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Abstract 
Since the beginning of the AIDS epidemic over thirty years ago, human 
immunodeficiency virus type 1 (HIV-1) has infected seventy-five million people 
and has claimed the lives of over thirty-six million people worldwide, making 
HIV/AIDS one of the most devastating global infectious disease epidemics in 
history. To date, no preventative vaccine or curative treatment exists for HIV-1 
infection. The availability of drugs to treat HIV-1 infection has led to drug 
resistance, which limits the utility of antiviral therapy.  This has provided the basis 
for the continual need for identifying new targets for antiviral drugs. 
This dissertation investigated the antiretroviral activity and mechanism of 
action for clofarabine, a purine nucleoside antimetabolite. Clofarabine was 
demonstrated to exert antiretroviral activity against both HIV-1 and human 
immunodeficiency virus type 2 (HIV-2). Studies directed at elucidating the 
antiretroviral mechanism of action support a model in which clofarabine acts as 
an inhibitor of ribonucleotide reductase, leading to imbalances in cellular dNTP 
pools, which reduces viral infectivity through an increase in the HIV-1 mutation 
rate. 
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Chapter 1 
General Introduction 
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The HIV Replication Cycle 
Since 1981, the human immunodeficiency virus (HIV) has been reported 
to infect seventy-five million people and has claimed the lives of over thirty-six 
million people worldwide (UNAIDS, 2013), making HIV/AIDS one of the most 
devastating global infectious disease epidemics the world has ever seen. HIV is 
a member of the lentivirus genus in the Retroviridae family of viruses. The ability 
of HIV to transform its single stranded, positive sense RNA genome into double 
stranded DNA revolutionized the central dogma of biology and is the genetic 
hallmark of all retroviruses. Many retrovirologists see reverse transcriptase (RT), 
the enzyme responsible for catalyzing this reaction, as the defining protein of this 
viral family. 
Six major steps comprise the life cycle of HIV: 1. Binding and Fusion 2. 
Uncoating and Reverse Transcription 3. Integration 4. Viral RNA and Protein 
Expression 5. Budding 6. Maturation (Figure 1-1). When an HIV viral particle 
infects a cell, the viral gp120 envelope protein interacts with the CD4 receptor of 
a susceptible cell. Following this interaction, gp120 undergoes a conformational 
change, exposing the viral gp41 fusion peptide. Depending upon the target cell 
type, the fusion peptide interacts with either a CCR5 coreceptor (macrophages) 
or a CXCR4 co-receptor (CD4-positive T-cells). Following another conformational 
change, the bilayers of the target cell and the viral particle fuse together. Fusion 
results in entry of the viral core into the cellular cytoplasm, which is followed by 
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uncoating and the continuation of reverse transcription, which begins in the viral 
core. 
The exact timing of the uncoating of the viral capsid vis-à-vis reverse 
transcription is a matter of debate, as reviewed in (Arhel, 2010). Viral particles 
contain both the RT enzyme and two copies of the HIV RNA genome within their 
cores (Nikolaitchik et al., 2013). The capsid lattice of the HIV-1 core has gaps of 
up to ten nanometers (Li et al., 2000), large enough for dNTP’s from the target 
cell and for small molecule inhibitors of RT to passively diffuse into it. The 
activation state and dNTP concentration of the target cell can influence the timing 
and successful completion of reverse transcription (Doitsh et al., 2010). 
Reverse transcription is a complicated, but well-studied process, as 
reviewed in (Sarafianos et al., 2009). Briefly, reverse transcription initiates when 
a tRNA-lys3 primer binds to the primer binding site (PBS) in the HIV genomic 
RNA. The heterodimeric RT begins synthesis of single stranded viral DNA, while 
simultaneously degrading the genomic RNA template. This single stranded 
strong stop DNA hybridizes with a complementary RNA sequence on the 
opposite end of the viral RNA genome, undertaking the “first jump.” Elongation of 
the minus strand follows, which is in turn followed by positive strand DNA 
synthesis. Positive strand synthesis requires priming from the central polypurine 
tract (PPT) and uses the minus strand vDNA as a template. Strand displacement 
synthesis extends the positive stranded vDNA. RNA primer removal follows, 
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which facilitates the second jump and resulting circularization of the double 
stranded viral DNA. 
Figure 1-1 The HIV Life Cycle. The HIV life cycle is defined by six major steps: 1. Attachment 
and entry to the receptor/coreceptor 2. Uncoating of the viral capsid 3. Reverse transcription 4. 
Transcription and translation of viral mRNAs and proteins 5. Assembly and budding and 6. 
Maturation of the viral particle to produce a conical shaped core. 
Upon completion of reverse transcription, the newly formed double- 
stranded viral DNA linearizes, is actively imported into the nucleus and integrates 
into the host chromosomal DNA (Katz et al., 2003). Following integration, the 
cellular machinery makes RNA copies of the virus, which viral accessory proteins 
help export. Subsequently, cellular proteins translate some of these viral RNA’s 
into viral proteins. Other, full length RNAs dimerize and are packaged into 
budding HIV-1 particles as viral genomes, along with many viral and some host 
proteins. Upon budding, HIV protease processes the viral Gag protein, and the 
resulting viral capsid monomers multimerize to form the mature viral core, in a 
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shape approximating a fullerene cone. The resulting mature HIV particles may 
then infect susceptible target cells. 
Antiretroviral Drugs: HIV Treatment and Prevention 
Disruption of any of the steps in the HIV life cycle represents an 
opportunity to stop viral replication. No preventative vaccine or curative treatment 
exists for HIV. Antiretroviral drugs have provided the most powerful tool to stop 
the loss of life associated with the HIV/AIDS epidemic. Currently, the United 
States Food and Drug Administration (FDA) has approved six classes of 
medications to treat HIV-1, including entry inhibitors, fusion inhibitors, nucleoside 
reverse transcription inhibitors (NRTIs), non-nucleoside reverse transcription 
inhibitors (NNRTIs), integrase inhibitors and protease inhibitors (Arts & Hazuda, 
2012). In the late 1990’s, Dr. David Ho, who first suggested the concept of highly 
effective antiretroviral therapy (HAART), proposed long-term suppression of HIV 
in patients required treatment with at least three drugs from two classes of anti- 
HIV medications (Perelson et al., 1996). Soon after, clinical trials featuring 
different combinations of three HIV drugs confirmed the success of the HAART 
approach in patients (Gulick et al., 1997; Montaner et al., 1998). 
Today, HAART remains the gold standard in HIV treatment. HAART has 
saved millions of lives and has allowed many people to achieve undetectable 
viral plasma loads (UNAIDS, 2013). The benefits of HAART, however, extend 
beyond individual life-saving treatment. The utilization of effective HAART can 
also prevent new HIV infections on a public health level. In San Francisco, the 
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reduction in community viral loads due to widespread HAART led to lower 
transmission of HIV throughout the population (Das et al., 2010). Subsequent 
studies demonstrated HAART could reduce HIV transmission in HIV-1 
serodiscordant couples by up to ninety-six percent (Anglemyer et al., 2013; 
Cohen et al.). In 2011, Science magazine named “HIV treatment as prevention” 
the scientific breakthrough of the year (Cohen). 
The ability of anti-HIV drugs to prevent not only the transmission but also 
the acquisition of HIV has also been demonstrated. In 2012 the FDA approved 
the NRTI’s emtricitabine and tenofovir, marketed together in one pill as Truvada, 
for use in pre-exposure prophylaxis (PrEP), after clinical trials showed daily 
Truvada reduced the rates of HIV-1 acquisition for populations at high risk for 
HIV-1 infection (Baeten & Celum, 2013; Celum, 2011; Murnane et al.). These 
findings followed in the intellectual footsteps of the earlier success of the use of 
HIV-1 drugs for prevention of mother to child transmission of HIV (PMTCT) 
(CDC, 1994a; b; Mofenson et al., 2009) and post-exposure prophylaxis for HIV-1 
(PEP) (Cardo et al., 1997). Many anti-HIV microbicides under development to 
prevent HIV also contain anti-retroviral drugs. 
HIV Drug Resistance Creates a Constant Need for Novel HIV Therapeutics 
Though anti-HIV-1 drugs ushered in a life-saving revolution to the 
HIV/AIDS epidemic, drug resistance immediately presented a threat to the 
sustained success of the fight against the virus (Larder et al., 1989a; Larder & 
Kemp, 1989; Larder et al., 1989b). HIV has evolved drug resistance to every 
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drug in each class of FDA approved anti-HIV therapeutics. HIV drug resistance is 
such a well-established issue, FDA guidance states sponsors developing anti- 
HIV-1 drugs should include characterization of HIV-1 drug resistance mutations 
and cross-resistance profiles in their submissions to the agency (HHS, 2013). 
Drug resistance reduces the efficacy of HAART and results in rebounds in 
HIV-1 viral loads. In individual patients, viral load increases are correlated with 
the reductions in CD4+ T-cell populations that can lead to AIDS. Viral load 
increases in patients experiencing drug resistance related treatment failure can 
also result in the transmission of drug resistant virus. The transmission of drug 
resistant virus decreases the treatment options for newly HIV infected people. 
The Centers for Disease Control (CDC) recently reported an increase in the 
percentage of transmitted drug resistant HIV-1 in the United States (Taylor et al., 
2013). Although it is has not yet been demonstrated as a serious problem, 
increased resistance to anti-HIV-1 drugs could also result from the use of these 
drugs to prevent HIV-1 infection. In order to extend the lives of treatment 
experienced patients and of patients newly infected with drug resistant HIV, 
scientists must constantly develop more anti-HIV drugs with different drug 
resistance profiles. The high cost of drug resistance and the essential role drugs 
play in combating the epidemic (Krentz et al., 2013) have led to extensive studies 
describing how drug resistance develops and spreads. 
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The Evolution of HIV Drug Resistance and its Impact on Viral Fitness 
Mutations resulting in amino acid changes in HIV viral proteins provide the 
molecular genetic basis for the acquisition of drug resistance (Menendez-Arias, 
2013; Wainberg et al., 1993). HIV drug resistance evolves so easily in large part 
because of the error prone nature of the HIV-1 reverse transcriptase enzyme 
(Boyer et al., 1992). RT-based errors provide the primary force responsible for 
HIV’s high mutation rate (Mansky & Temin, 1995). When combined with the 
staggering replicative capacity of HIV-1 in untreated patients (Perelson et al., 
1996), theoretical calculations show the HIV-1 mutation rate results in the 
mutation of every base in the roughly 9.7 kilobase HIV-1 genome every day. 
Experimental evidence has confirmed the high mutation rate of HIV-1(Mansky & 
Temin, 1995). The high number of HIV viral mutants results in the development 
of a genetically diverse HIV-1 quasispecies, rather than a genetically identical 
wild type HIV-1 population in the host. HIV-1 drug treatment results in the 
outgrowth of viral mutants that confer a selective advantage toward replicating in 
the presence of the drug, allowing a rebound in viral load in HIV infected patients. 
Reverse transcriptase, therefore, fundamentally drives the evolution of 
HIV, allowing the virus to respond to selective pressures. RT synthesizes the 
double stranded DNA copy of the HIV genome that serves as the template for the 
production of all viral proteins and subsequently produced RNA genomes. Errors 
made in the viral DNA can lead to drug resistance mutations in any part of the 
HIV genome – including in the coding region of RT itself. Mutations in RT not 
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only lead to drug resistance to RT inhibitors, they can also alter the course of HIV 
evolution and viral fitness. Drug resistance mutations in RT impact the mutation 
rate (Mansky et al., 2003), catalytic rate (Deval et al., 2005), structure (Arnold et 
al., 1996; Huang et al., 1998; Tu et al., 2010; Zhan et al., 2009), dNTP and dNTP 
analog binding ability (Gao et al., 2000) and dNTP analog excision rate 
(Matamoros et al., 2004; Xu et al., 2009) of the virus. 
Changes in these RT related parameters in turn can result in alterations to 
the replicative capacity and reduce the overall fitness of the virus, in laboratory 
experiments and in patients (Bouchonnet et al., 2005; Dapp et al., 2013a; Weber 
et al., 2007). Dynamic mathematical models have been generated as a means to 
estimate the impact of drug resistance mutations on HIV fitness and evolution 
(von Kleist et al., 2012). Anti-HIV drug therapies that intentionally drive HIV 
evolution towards less fit viral genotypes have been proposed, but have yet to be 
developed. Investigations of the impact of NRTI drug resistance mutations on the 
course of HIV evolution suggest that resistance, in particular the M184V/M184I 
and K65R/L74V mutations, can reduce the fitness of the virus, especially under 
limiting dNTP conditions (Back & Berkhout, 1997; Bouchonnet et al., 2005; Deval 
et al., 2004). Ongoing drug development efforts, including the investigation of 
ribonucleotide reductase inhibitors (RNRIs) (Rawson et al., 2013) and lethal 
mutagens (Clouser et al., 2010; Dapp et al., 2009), also may provide the 
additional tools and information necessary to pave the way for this objective. 
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NRTIs: Mechanism of Action and Drug Resistance and the Impact on Viral 
Fitness 
Of all HIV proteins, researchers first successfully targeted RT as an 
antiviral drug target. The thymidine analog zidovudine (AZT) was the first anti- 
HIV-1 drug to show activity in clinical trials (Fischl et al., 1987). AZT, like all other 
nucleoside reverse transcriptase inhibitors (NRTIs), acts as a viral DNA chain 
terminator to inhibit HIV replication. The structure of NRTIs contributes to their 
antiviral activity - NRTIs lack a 3’-hydroxyl group on their sugar moiety. When RT 
incorporates a phosphorylated NRTI into HIV DNA, the lack of the 3’-hydroxyl 
prevents the formation of the 5′,3’-phosphodiester bond that is necessary for 
extension of the DNA chain. Currently, seven unique NRTIs are FDA approved to 
treat HIV-1 infection - abacavir (ABC), emtricitabine (FTC), lamivudine (3TC), 
stavudine (d4T), zidovudine (AZT), didanosine (ddI) and tenofovir disoproxil 
fumarate (TDF). The drug resistance mutations and pathways for all of these 
NRTIs have been extensively characterized, as discussed in (Arts & Hazuda, 
2012; Lawyer et al., 2011; Menendez-Arias, 2013; Sarafianos et al., 2009). 
At least two mechanistic pathways – excision and exclusion – can lead to 
HIV viral RT mutants resistant to NRTIs. In the excision mechanism, the 
thymidine analog mutations (TAM’s) mutations in RT, including T215F/T215Y, 
K219E/K219Q, M41L, D67N, K70R, and L210W increase the enzyme’s ability to 
remove chain-terminating activated NRTIs from the growing viral DNA chain via 
ATP mediated phosphorlysis (Meyer et al., 1999). Interestingly, HIV-1, but not 
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HIV-2, can use the excision mechanism to facilitate drug resistance (Boyer et al., 
2012; Boyer et al., 2006). Accordingly, the TAM mutations have been reported to 
have no effect on zidovudine sensitivity for HIV-2 and are rarely seen in HIV-2 
positive individuals on NRTI containing treatment regiments (Charpentier et al., 
2014; Smith et al., 2009). 
In the exclusion mechanism, RT mutations, including M184I, M184V, 
K65R, K70E, V75I, and L74V grant the enzyme a heightened ability to prevent 
triphosphorylated NRTIs from incorporating into the viral DNA (Miranda et al., 
2005; Tisdale et al., 1993). Some of these mutations can also decrease the 
ability of RT to incorporate endogenous nucleotides, especially under low dNTP 
concentrations, thereby contributing to fitness reductions (Bouchonnet et al., 
2005; Deval et al., 2004). Both HIV-1 and HIV-2 can utilize the exclusion 
mechanism of RT resistance, and these resistance mutations have been 
described in individuals infected with either virus (Boyer et al., 2012; Charpentier 
et al., 2014; Menendez-Arias & Alvarez, 2014; Parkin & Schapiro, 2004). 
When dNTP pool levels reach critically low levels, neither HIV-1 nor HIV-2 
RT can continue to synthesize viral DNA (Boyer et al., 2012). Given that RT 
competitively incorporates endogenous dNTPs and NRTIs into vDNA, the ratio of 
endogenous dNTPs to NRTIs can impact the development of drug resistance 
(Amie et al., 2013a). Accordingly, drugs or cellular factors that affect the 
endogenous dNTP pool levels or modulate the phosphorylation levels of NRTIs 
can also influence how sensitive drug resistant RT mutants become to NRTIs 
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(Back et al., 1996; Balzarini, 2000). Ribonucleotide reductase inhibitors have 
been used in combination with NRTIs to enhance the chain terminating activity of 
these drugs, as well as to resensitize NRTI drug resistant viruses to NRTI 
treatment (Frank et al., 2004a; Heredia et al., 2000; Palmer et al., 1999). The 
combination of RNRIs and viral mutagens also can increase the HIV-1 mutation 
frequency and synergistically reduce HIV-1 infectivity (Clouser et al., 2010). 
These results, along with the anti-viral effect of RNRIs (Gao et al., 1993; Heredia 
et al., 2000) and the antiviral cellular host restriction factor triphosphohydrolase 
SAMHD1 (Amie et al., 2013a; Baldauf et al., 2012; Berger et al., 2011), indicate 
dNTP pool levels themselves may represent an anti-viral drug target. 
The Cellular Maintenance of dNTP Pools: Ribonucleotide Reductase and 
the Innate Immune Response 
All cellular organisms as well as DNA viruses and viruses that go through 
a DNA intermediate in their life cycles require dNTPs to replicate and repair their 
DNA-containing genomes. Cells tightly regulate the production, timing and ratios 
of dNTP pools, which helps maintain nuclear and mitochondrial genome integrity 
and prevent viral infection and cancer (Kim et al., 2012; Rampazzo et al., 2010). 
The ancient and highly conserved enzyme ribonucleotide reductase (RNR) 
serves as the master creator and regulator of dNTP pools in cells (Reichard, 
1985). As the sole human enzyme responsible for reducing NDPs to dNDPs, 
RNR governs the rate limiting step in dNTP synthesis (Reichard et al., 1961; 
Szekeres et al., 1997). Comprised of a large, constitutively expressed regulatory 
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subunit (RRM1) and a small, cell cycle dependent (RRM2) or DNA damage 
induced (p53R2) catalytic subunit (Tanaka et al., 2000), RNR has served as both 
an anti-cancer and an antiviral drug target (Szekeres et al., 1997). 
For successful replication, viruses that use DNA as the building blocks of 
their genomes must gain access to cellular concentrations of dNTPs in excess of 
the Kd of the polymerases that synthesize viral DNA. More efficient viral 
replication occurs when cellular dNTP concentrations exceed the Km of the 
polymerases (Diamond et al., 2004). RNR produces high concentrations of 
dNTPs in the cytoplasm during S phase of the cell cycle (Leeds et al., 1985). 
Resting cells, however, have much lower concentrations of cytoplasmic dNTPs 
(Hakansson et al., 2006). Many DNA-containing viruses that replicate in the 
cytoplasm can only efficiently infect cells undergoing cell division, because the 
dNTP concentrations in many resting cell types are too low to support the 
complete synthesis of their genomes (Baldauf et al., 2012; Capella et al., 2012; 
Pieroni et al., 1999). Interestingly, some herpes viruses encode viral 
ribonucleotide reductases in order to help overcome this block, further 
demonstrating the crucial role dNTP levels can play in viral replication (Swain & 
Galloway, 1986). 
Intrinsic cellular immune defenses have evolved to lower cellular dNTP 
pool concentrations to defend against viral infection. The expression of the 
triphosphohydrolase SAMHD1 in myeloid cell lineages renders these cell types 
highly impermissive to HIV-1 infection (Laguette et al., 2011). HIV-2 encodes the 
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Vpx protein to target SAMHD1 for degradation (Ahn et al., 2012), allowing the 
virus to replicate in macrophages (Amie et al., 2013a) and, unlike HIV-1, also in 
dendritic cells (Lahaye et al., 2013). Without Vpx, however, HIV-2 cannot 
efficiently infect macrophages (Kappes et al., 1991). The HIV-2 RT enzyme has 
lower activity than HIV-1 RT (Boyer et al., 2012), which may partially help explain 
why HIV-1, which does not encode Vpx, can (albeit inefficiently) infect 
macrophages (Diamond et al., 2004), while HIV-2 heavily relies on Vpx for this 
ability. SAMHD1 has also been shown to prevent other DNA viruses, including 
HSV-1 and Vaccinia virus, from infecting cell types with low dNTP pools 
(Hollenbaugh et al., 2013; Kim et al., 2013). The increasingly understood impact 
on fluctuations in dNTP pools on the permissiveness of cells to DNA-dependent 
virus infection suggests RNR may be a timely drug target to revisit for the 
treatment and prevention of DNA viruses and retroviruses, including HIV-1 and 
HIV-2 (Allouch et al., 2013). 
Antiviral Ribonucleotide Reductase Inhibitors and Their Mechanisms of 
Action 
The Food and Drug Administration has approved many small molecule 
inhibitors of ribonucleotide reductase (RNRIs). Collectively, RNRIs include drugs 
that target the large or small subunits of RNR and utilize a diverse variety of 
mechanisms to inhibit the enzyme, as reviewed in (Nordlund & Reichard, 2006). 
RNR inhibition decreases one or more dNTP pools in cells, which can be 
reversible or irreversible. Hydroxyurea (HU), a non-nucleoside RNR, was the first 
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in class to be FDA approved. Subsequently, many more nucleoside and non- 
nucleoside analog RNRIs have become available on the U.S. market. 
The RNRIs hydroxyurea (Lori et al., 1994), gemcitabine (Clouser et al., 
2010), resveratrol (Heredia et al., 2000) and deferoxamine (Rawson et al., 2013) 
have anti-HIV activity in cell culture. In the 1990s and early 2000s, many 
physicians prescribed HU off-label to treat HIV-1 infection. HU, while having no 
anti-HIV-1 efficacy as monotherapy in patients (Frank et al., 2004a; Giacca et al., 
1996), decreases HIV-1 viral loads, when used in combination with NRTIs, 
especially ddI (De Antoni et al., 1997; Frank et al., 2004a). Subsequent toxicity 
concerns, however, have largely led to the discontinued use of HU as a 
component of HAART. 
The mechanistic studies of HU mediated inhibition of HIV show HU's 
ability to decrease the concentration of dNTP pools correlates with its antiviral 
effect (Bakshi et al., 2007). Primer extension assays illustrate that in stimulated 
PBMCs, HU can deplete dATP pools for over 48 hours, while simultaneously 
increasing other dNTP pools (Gao et al., 1995). Another antiviral non-nucleoside 
RNRI, resveratrol, in contrast, has been reported to deplete all dNTP pools 24 
hours after treatment of HL-60 cells (Horvath et al., 2005). Depletions of dNTP 
pools that alter the naturally occurring cellular ratios of the four endogenous 
dNTPs to one other can lead to the inhibition of viral replication in at least two 
distinct ways: 1. By increasing the viral mutation rate beyond the error threshold 
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of the virus (lethal mutagenesis) and 2. By reducing viral DNA synthesis. Each of 
these mechanisms and their complexities are addressed. 
Lethal Mutagenesis: Cellular dNTP Pool Modulations Increase HIV Mutation 
Eurkaryotic cells maintain dNTP pools at levels consistent with the DNA 
replication needs of the cell. Though the concentrations, ratios, and overall levels 
of dNTP pools can vary from cell type to cell type, the endogenous 
concentrations of the four dNTP pools are not equimolar in mammalian cells 
(Mathews & Ji, 1992; Vartanian et al., 1997). In most mammalian cells the 
concentrations of the dNTP pools vary, in the order of [TTP] > [dATP] > [dCTP] > 
[dGTP] (Mathews & Ji, 1992; Zhang & Mathews, 1995). In primary cells, the non- 
equimolar balance of eurkaryotic dNTP pools has been found to promote 
increased fidelity over equimolar dNTP pools in vitro (Martomo & Mathews, 
2002). In contrast, groups have suggested these unequal pool levels are non- 
ideal for HIV-1 replication. Notably, the addition of thymidine to PMBCs has an 
antiviral effect that can be partially reversed by the addition of deoxycytidine 
(Meyerhans et al., 1994). Though Meyerhans et. al. did not characterize the 
molecular mechanisms responsible for the antiviral effect of thymidine, they note 
the incomplete recovery of viral infectivity upon addition of deoxycytidine after 
thymidine treatment could have been due to an increase in viral mutation 
(Meyerhans et al., 1994). 
The idea that increases in viral mutational burden can have antiviral 
effects is related to the concept of lethal mutagenesis. In the context of viral 
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infection, lethal mutagenesis is defined as the point where an increase in 
mutation leads to the increasing production of non-infectious progeny virions, 
eventually resulting in extinction of the viral population. The specific threshold at 
which the viral population experiences genetic collapse and the virus can no 
longer successfully replicate has been referred to as extinction catastrophe 
(Dapp et al., 2013b). The amount of mutation required for different viruses to 
reach their extinction catastrophe thresholds varies. The theoretical measure of 
robustness evaluates the extent of mutation a virus can withstand before 
reaching its extinction catastrophe threshold (Elena et al., 2006). 
As an antiviral strategy, lethal mutagenesis is theorized to work best for 
viruses that have low robustness (Elena et al., 2006). Lethal mutagenesis can 
have genetic or environmental causes. The genetic destruction of a viral 
population might occur due to a mutation in key viral replication or repair 
enzymes that lead to a strong mutator phenotype. Or, mutagenic compounds 
might be added to the viral replication environment, leading to enhanced viral 
mutation through mutagen incorporation, changes in dNTP pools leading to 
overall increases in base misincorporation, increases in DNA extension without 
proofreading after base misincorporation, increases in one or more “next 
nucleotide” nucleotide sequence dependent errors, chemical modification of DNA 
by alkylating or other similar agents (Drablos et al., 2004), or a combination of 
these mechanisms. 
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Viral population size, basal mutation rate, genetic robustness, replication 
rate, and the accessibility of mutagenic factors to reach the entire viral population 
can all impact the timing, evolution and dynamics of lethal mutagenesis. It has 
been suggested that the high mutation rate and low robustness of RNA viruses 
and retroviruses make them easily amenable to extinction via lethal mutagenesis 
(Dapp et al., 2013a; Loeb et al., 1999). Indeed, the lethal mutagenesis of RNA 
viruses (Ortega-Prieto et al.) including HIV (Clouser et al., 2010; Dapp et al., 
2009) have been demonstrated in cell culture via the incorporation of mutagenic 
drugs. What remains uncertain, however, is whether an imbalance in dNTP pools 
alone can be mutagenic enough to cause the lethal mutagenesis of HIV. 
At least one study has demonstrated a correlation between increasing HU 
concentration and corresponding increases in both dNTP pool imbalances and 
higher retroviral mutation rates in murine leukemia virus (MLV) and spleen 
necrosis virus (SNV) (Julias & Pathak, 1998). This same study also found dose- 
dependent increases in thymidine increased retroviral mutation rates even more 
than HU, despite resulting in a very different profile of dNTP pool imbalances 
(Julias & Pathak, 1998). Despite finding an association between reduced viral 
titer and an increase in mutation rate, the authors speculated heightened 
mutation rates were not responsible for the majority of the antiviral effect of either 
HU or thymidine. Instead, they state the near five-fold increase in viral mutation 
rate they observed in one cycle of replication could theoretically only account for 
10% of the greater than 60% or 90% reductions in titer reduction observed in 
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their study from thymidine or HU treatment, respectively. Julias et. al. suggest the 
majority of the HU’s antiviral effect likely came from a reduction in DNA synthesis 
due to overall lowered dNTP pools and that thymidine’s antiviral effect could be 
due to cytotoxicity (Julias & Pathak, 1998). Neither of these hypotheses were 
directly tested in this study, though notably others had previously demonstrated 
HU treatment is associated with depletions in vDNA synthesis and that HU’s 
potency is higher in cell lines with lower dNTP pools (Lori et al., 1994). 
Other authors have noted HU treatment in cell culture results in a 
decrease in viral titer and a corresponding increase in HIV-1 RT template 
switching and recombination (Nikolenko et al., 2004). This increase in template 
switching was hypothesized to be due to a dNTP depletion related reduction in 
DNA synthesis (Nikolenko et al., 2004). Notably, in this study, no tests were done 
to measure whether HU increased or decreased viral mutant frequency. In the 
absence of HU treatment, however, this same study reported that many NRTI 
drug resistance mutations also led to an increase in template switching, and that 
this was correlated with reduced dNTP binding, increased pyrophosphorlysis, 
greater RT fidelity, lower viral titer, and lower mutant frequencies (Nikolenko et 
al., 2004). It is not clear whether some or all of these trends would hold true 
under HU treatment. 
Other studies suggest that if Nikolenko et. al. had investigated the impact 
of HU, they may have found that unlike some NRTI drug resistance mutations 
that increase RT fidelity, HU can increase mutant frequency. HU treatment has 
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been shown to be associated with a 6.2 fold increase in the mutant frequency of 
wild type HIV-1 RT, even in one round of replication in a cell line undergoing 
continuous division (Mansky, 2003). When multidrug resistant HIV-1 RT was 
treated with HU, the mutant frequency increased 21.8 times vis-à-vis wild type 
HIV-1 RT with no drug treatment (Mansky, 2003). In contrast to Julias et. al., the 
authors of this study report HU’s increase in viral mutation frequency likely 
accounted for the decrease in viral titer observed under HU treatment (Mansky, 
2003). Similar results in these studies were found with thymidine treatment 
(Mansky, 2003). Using a different assay, studies with the RNRIs gemcitabine and 
resveratrol have also independently shown these drugs increase HIV-1 mutant 
frequency in a dose-dependent fashion (Rawson et al., 2013). These authors 
also suggest that non-specific increases in viral mutation rate play a large role in 
the anti-HIV-1 activity of these drugs. Mutant spectra result showing an increase 
in mutations on a genetic level further support the finding of increased 
mutagenicity using phenotypic assays. 
When HIV-1 proviruses have been sequenced from RNRI-treated cells, 
mutant spectra analysis has revealed most of the detected mutations are G-to-A 
transitions (Rawson et al., 2013). For many years, wild type HIV-1 proviral clones 
have also been isolated that contain high rates of G-to-A transition mutations, 
including some sequences with extensive G-to-A sequence hypermutation (Li et 
al., 1991b; Mansky & Temin, 1995). Prior to the discovery of APOBEC3 family 
members, the high TTP, lower dCTP pyrimidine dNTP pool bias in HIV-1 target 
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cells was hypothesized to be responsible for these G-to-A hypermutants 
(Martomo & Mathews, 2002; Vartanian et al., 1997). 
In the early 2000s, however, APOBEC3 proteins were found to restrict 
HIV-1 replication at least in part by causing G-to-A hypermutation (Sheehy et al., 
2002; Zheng et al., 2004). Today, G-to-A hypermutation is nearly universally 
considered the hallmark of APOBEC3 mutation, especially when the majority of 
the individual mutations are in the sequence context of GG and GA dinucleotides 
(Chaipan et al., 2013). To cause hypermutation, APOBEC3 proteins must be 
packaged into budding virions (Mangeat et al., 2003; Mariani et al., 2003). During 
reverse transcription, the APOBEC3 proteins APOBEC3G, APOBEC3F, 
APOBEC3DE, and APOBEC3H can processively deaminate cytidine to uracil in 
minus strand single stranded viral DNA (Chelico et al., 2006; Hultquist et al., 
2011). This leads to G-to-A transition mutations in the positive strand of HIV 
DNA. High levels of uracil in the resulting single-stranded DNA transcripts can 
lead to the degradation of viral DNA (Mangeat et al., 2003). Any HIV-1 viral DNA 
that does integrate, moreover, often contains G-to-A hypermutated DNA 
(Mangeat et al., 2003; Russell et al., 2009). 
Interestingly, different target cell types infected with Vif-containing HIV-1 
viral like particles produced from the same cell line can show different rates of G- 
to-A hypermutation (Holtz & Mansky, 2013). These findings suggest the target 
cell environment may also influence the extent of APOBEC3 associated 
hypermutation. In silico modeling studies have questioned whether APOBEC3 
21 
 
alone or APOBEC3 in combination with endogenous dNTP pool imbalances 
explains the G-to-A hypermutation observed in HIV-1 infected cells (Deforche et 
al., 2007). Taken together with the older literature demonstrating the TTP to 
dCTP pool level ratio (Martomo & Mathews, 2002; Vartanian et al., 1997) and 
“next nucleotide” effects (Zhang & Mathews, 1995) can impact the rate and 
sequence context of G-to-A hypermutation, these studies suggest modulations in 
dNTP pools associated with SAMHD1 or RNRI treatment may also influence the 
G-to-A hypermutation of APOBEC3 proteins. 
Regardless of the contributions APOBEC3 proteins vs. target cell dNTP 
pools make to G-to-A hypermutation, components of the intrinsic host immune 
response to HIV infection and perhaps also the homeostatic state of dNTP pools 
in immune cells selectively increase viral mutation. Experimental evidence from 
tissue culture indicates increases in G-to-A hypermutation correlate with 
reductions in viral infectivity. To date, high G-to-A proviral hypermutation has not 
been shown to cure HIV in any patient, though higher patient APOBEC3G levels 
have been associated with lower HIV proviral burden (De Pasquale et al., 2013). 
On an infected cell basis, processive G-to-A hypermutation may theoretically 
lethally mutate an individual HIV provirus that subsequently integrates, leading to 
the production of only non-infectious viral particles from that cell. Especially in the 
presence of Vif, APOBEC3 proteins may also sub-lethally mutate HIV-1 
proviruses (Sadler et al., 2010). Sublethal APOBEC3 associated mutations may 
contribute to the evolution of HIV drug resistance mutations (Mulder et al., 2008). 
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The advent of drug resistance mutations, however, does not mean HIV drug 
resistance will immediately emerge. Other factors, including dNTP pool levels in 
target cells, also affect whether the phenotype of drug resistance will emerge in 
an HIV-1 infected individual on drug treatment. 
As previously mentioned, many studies have shown that HU and other 
RNRIs can re-sensitize NRTI resistant HIV RT mutants to NRTI treatment 
(Balzarini, 2000; Heredia et al., 2014; Heredia et al., 2000; Heredia et al., 2013; 
Lori et al., 1997). The results from at least one small clinical study, however, 
have also shown HU treatment may result in the enhanced generation of drug 
resistance mutations (De Antoni et al., 1997). De Antoni and colleagues reported 
that when comparing HU + ddI vs. ddI monotherapy treated patients, 50% of 
patients in the HU + ddI treatment arm developed resistance to ddI, while only 
25% of those in the ddI monotherapy arm developed these resistance mutations 
over a 24 week time period (De Antoni et al., 1997). Patients in the HU + ddI 
treatment arm, however, also experienced a one log greater reduction in their 
viral loads (De Antoni et al., 1997). The authors indicate the comparative 
reduction in viral load was likely due to HU’s reduction in dATP pools allowing for 
a relative greater potency of ddI, resulting in the continued inhibitory effects of 
ddI even in the presence of resistance mutations (De Antoni et al., 1997). 
The potential lesson from these and similar studies (Frank et al., 2004b) is 
that even if the imbalanced and depleted cellular dNTP pools resulting from 
RNRI treatment do lead to an increases in HIV-1 drug resistance mutations, it is 
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likely because these RNRIs also result in an overall increase in HIV-1 mutation 
frequency. This increased mutation frequency correlates with decreases in viral 
loads in HIV-1 positive patients, when RNRIs are given in combination with 
NRTIs, when compared to NRTI treatment alone. These data suggest part of the 
antiviral mechanism of action of RNRIs is likely related to lethal mutagenesis. 
Importantly, these results also suggest even if HIV-1 drug resistance 
genotypes do increase under RNRI treatment, drug resistance mutations may not 
actually lead to the phenotype of NRTI drug resistance in HIV-1 positive patients 
taking both NRTIs and RNRIs. This effect can occur through multiple 
mechanisms, including that RNRI’s can increase the relative ratio of NRTIs vis-à- 
vis dNTP’s by reducing one or more endogenous dNTP pools and/or by 
increasing the phosphorylation of the NRTIs (Gao et al., 1995). These 
modulations in dNTP pools and changes in phosphorylation patterns allow HIV-1 
RT to incorporate NRTIs, even in the presence of drug resistance mutations that 
lead to reduced NRTI binding and/or increased excision of these chain 
terminating drugs. 
RNRIs Reduce DNA Synthesis Through Depletions in dNTP Pools 
In addition to enhanced mutation, reductions in viral DNA synthesis also 
likely contribute to the anti-HIV activity of RNRIs, much like the antiviral 
mechanisms of some host immune factors. A reduction in one or more dNTP 
pools caused by antiviral immune responses or by RNRI administration can 
cause RT to pause until the limiting dNTP becomes available. If the required 
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dNTP does not materialize, RT may either attempt to switch genomic templates, 
(Nikolenko et al., 2004), or may fall off the template entirely, leading to abortive 
HIV infection. 
Hydroxyurea treatment administered to PBMCs during reverse 
transcription results in a near complete inhibition of HIV-1 infectivity (Gao et al., 
1994; Meyerhans et al., 1994) that subsequent adenosine administration largely 
overcomes (Meyerhans et al., 1994). Similarly, HU treatment of macrophages 
results in a reduction of viral DNA synthesis that dNTP precursor treatment can 
mostly reverse (Kootstra et al., 2000). These results indicate HU inhibits viral 
DNA synthesis by depleting dNTP pools during HIV-1 reverse transcription. The 
effects of cellular dNTP pool level modulations associated with cell cycle phase 
and/or the enzymatic activities of antiviral proteins further support this model. 
Notably, the naturally lower dNTP pools in non-dividing cells can result in 
lower rates of viral DNA synthesis. The low dNTP pools found in resting CD4 
positive T-cells lead to abortive HIV-1 infection that maps to the reverse 
transcription step of the HIV-1 life cycle (Zack et al., 1990; Zack et al., 1992). 
Stimulation of infected resting CD4 positive T-cells results in the rescue of HIV-1 
infection (Zack et al., 1992), likely because of the stimulation-associated increase 
in dNTP pools (Meyerhans et al., 1994). The extremely low dNTP concentrations 
in macrophages also result in comparatively less efficient HIV viral DNA 
synthesis (Diamond et al., 2004). 
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In addition, some host immune factors exploit lowering the rate of viral 
DNA synthesis as part of their antiviral mechanisms. To achieve its full antiviral 
effect, APOBEC3G not only hypermutates viral DNA, it also slows down the rate 
of reverse transcription by binding to the viral RNA template (Adolph et al., 2013). 
The slower rate of reverse transcription allows APOBEC3G more time to 
deaminate cytosines to uracils in minus strand HIV DNA, demonstrating a 
mutually beneficial link between a decrease in DNA synthesis rate and 
mutagenesis as antiviral mechanisms (Adolph et al., 2013). 
In the absence of Vpx, SAMHD1 associated decreases in dNTP pools 
upon HIV infection leads to a slower rate or a complete collapse of viral DNA 
synthesis (Kim et al., 2012). Given that SAMHD1 does not dephosphorylate 
NRTIs, a combination of SAMHD1 triphosphohyrdrolase activity leading to a 
depletion in endogenous dNTPs and NRTI treatment in macrophages may lead 
to an irreversible inhibition of HIV-1 viral DNA synthesis (Amie et al., 2013a). 
Summary 
Collectively, this chapter demonstrates the cellular maintenance of dNTP 
concentrations above the level required for RT catalysis is important for 
successful HIV viral DNA replication and infection (Amie et al., 2013b). 
Reductions in dNTP pools below the Km of HIV RT, whether naturally occurring 
or induced by RNRI’s, result in the slowing of viral DNA synthesis rates. Slower 
vDNA synthesis can result in the increased incorporation of: i. incorrect dNTP’s ii. 
ribonucleoside triphoshphates, iii. deoxynucleoside analogs, or iv. nucleoside 
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analogs, raising HIV’s mutation rate. Slower RT DNA catalysis rates also lead to 
more opportunity for APOBEC3G-associated hypermutation. Additionally, slower 
viral DNA replication decrease the overall number of viral genomes produced in 
an infected patient, per unit of time, thereby reducing viral fitness. 
Evidence from the literature suggests the intentional lowering of dNTP 
pools may contribute to the lethal mutation of many proviruses in HIV-infected 
patients or in cell culture. Whether or not the mutagenic effects of dNTP pool 
disruptions acting alone could ever result in the successful lethal mutagenesis of 
HIV, however, remains an open question. To date, the only examples of the 
lethal mutagenesis of HIV have been attributed to mutagenic nucleoside analogs 
acting alone or mutagenic analogs in combination with drugs that lower dNTP 
pools. 
Separation of the relative contributions increased mutation and reductions 
in viral DNA levels make to the molecular mechanism of action of RNRI’s poses 
a great technological and intellectual challenge. Increasing the difficulty of this 
challenge is the ability for the presence of many DNA lesions to lead to DNA 
destruction. Groups have reported viral DNA transcripts carrying many 
APOBEC3G-induced mutagenic lesions can be degraded before integration, 
showing APOBEC3 related increases in mutation can lead directly to reductions 
in viral DNA levels (Russell et al., 2009). It may be that the increased 
mutagenesis of viruses commonly results in associated depletions of viral DNA 
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that “muddy the waters” of the theoretical mutation-only mechanism of action 
attributed to lethal mutagenesis. 
Whether RNRIs act mostly through increased viral mutation rates or by a 
more general inhibition of viral DNA synthesis, their clinical utility as antiviral 
agents merits reconsideration. The human immune system itself uses both lethal 
mutagenesis and dNTP pool limitations to counteract viral infection. The HIV 
restriction of APOBEC3G, APOBEC3F, APOBEC3DE and APOBEC3H via G-to- 
A hypermutation demonstrates the human immune system exploits lethal 
mutagenesis as part of its natural defense mechanisms. The antiviral mechanism 
of action of SAMHD1 also shows the human body has naturally evolved to 
regulate dNTP pool levels as part of the antiviral response. RNRI’s have the 
unique ability to simultaneously inhibit wild type HIV replication and to re- 
sensitize NRTI resistant HIV mutants to NRTI treatment. This dual-pronged 
approach toward inhibiting HIV should be seen as increasingly important in a 
world where antiretroviral agents are used not only to treat HIV infection, but also 
to prevent the spread of the virus. 
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Chapter 2 
Characterization of antiretroviral drug activity using the time of drug 
addition assay 
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Abstract 
Human immunodeficiency virus type 2 (HIV-2) infects approximately 2 
million people worldwide. Compared to human immunodeficiency virus 1 (HIV-1), 
HIV-2 has significantly fewer treatment options and evolves drug resistance more 
quickly. The ribonucleotide reductase inhibitor (RNRI) hydroxyurea has been 
used clinically to treat HIV-1 infection. RNRIs deplete cellular dNTP pools, 
resulting in an inhibition of reverse transcription. To date, no systematic analysis 
has been conducted to test the efficacy of RNRIs against HIV-2, though studies 
have indicated HIV-2 may be more sensitive to reductions in dNTP pools. Our 
findings demonstrate the RNRIs gemcitabine, resveratrol and clofarabine as well 
as the mutagen 5-azacytidine have potent antiviral activity against both HIV-2 
and HIV-1 in parallel vector virus assays. Statistical analysis revealed that the 
EC50 of 5-azacytidine, clofarabine and resveratrol are lower for HIV-2 compared 
to HIV-1. Time of drug addition assays confirm that RNRIs act during the reverse 
transcription phase of HIV-1 and HIV-2 replication. These results indicate that 
RNRIs and viral mutagens may be viable drug classes to add to the treatment 
repertoire for HIV-2 patients, especially those for whom other treatment options 
are limited. 
Introduction 
HIV-2 infected individuals are primarily of west African descent and many 
of the HIV-2 cases worldwide are attributed to immigrant populations of west 
Africans living abroad.(Campbell-Yesufu & Gandhi, 2011; Costarelli et al., 2008; 
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Rey et al., 1989; van der Ende et al., 1990). The low prevalence of HIV-2 
compared to HIV-1 is attributed to its low infectivity. HIV-2 is considered a 
naturally attenuated infection and HIV-2 infected individuals are more likely to 
have lower viral RNA levels and are less likely to progress to AIDS compared to 
HIV-1 infected individuals (Bouree et al., 1995; Campbell-Yesufu & Gandhi, 
2011; Costarelli et al., 2008; Soares et al., 2011). However, when HIV-2 does 
progress to AIDS, infected individuals have fewer treatment options than those 
infected with HIV-1, because not all anti-HIV-1 drugs inhibit replication of HIV-2. 
Furthermore, HIV-2 has been reported to have lower genetic barriers to the 
evolution of multidrug resistance than HIV-1, further narrowing the already-limited 
HIV-2 drug treatment options (Gottlieb et al., 2009; MacNeil et al., 2007; 
Menendez-Arias & Alvarez, 2014; Rodes et al., 2000; Smith et al., 2009; 
Witvrouw et al., 2004). 
The RNRI hydroxyurea (HU) was used alone and in combination with 
NRTIs to treat HIV-1 before more specific drugs were available (Biron et al., 
1995; Frank et al., 2004a; Lori et al., 1997). However, the toxicity of hydroxyurea 
made it a less than ideal drug for use in HIV-1 infected individuals. Several 
studies have since demonstrated the anti-HIV-1 activity of other, potentially less 
toxic, RNRIs in cell culture and in mouse models (Clouser et al., 2012a; Clouser 
et al., 2011; Clouser et al., 2012b; Rawson et al., 2013). HU and other RNRIs 
work by inhibiting RNR, a cellular enzyme that reduces NDPs to dNDPs in the 
cytoplasm of cells (Xie et al., 2014). Through the reduction of NDPs, RNR 
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provides cells with the dNTPs which are used to replicate the host DNA, but 
which can also be used to enable replication of DNA viruses and retroviruses. 
Both HIV-1 and HIV-2 require cellular dNTPs to complete reverse transcription. 
Multiple independent lines of evidence led us to hypothesize HIV-2 RT 
might be more sensitive than HIV-1 RT to reductions in dNTP pools. HIV-2 RT is 
less processive than HIV-1 RT (Boyer et al., 2012; MacNeil et al., 2007; Post et 
al., 2003), and this effect is enhanced under reduced dNTP pools (Boyer et al., 
2012). Thus, the depletion of dNTP pools by RNRIs could hinder the ability of 
HIV-2 to complete reverse transcription to a greater extent than HIV-1. 
Additionally, unlike HIV-1, HIV-2 encodes the Vpx protein (Clavel et al., 1986), 
which degrades the cellular triphosphorhydrolase SAMHD1 (Ahn et al., 2012). 
SAMHD1 degradation results in an increase in dNTP pool concentrations, which 
allows HIV-2 to replicate in cells with low dNTP concentrations such as 
macrophages (Baldauf et al., 2012; Kim et al., 2012; Lahouassa et al., 2012; St 
Gelais et al., 2012). In contrast, HIV-1 which does not encode Vpx, can replicate 
in macrophages (Diamond et al., 2004), without counteracting SAMHD1(Nguyen 
et al., 2014). In summary, efficient replication of HIV-2 is dependent on the HIV-2 
virally encoded protein Vpx, while HIV-1 replication is not. Thus, the role of Vpx 
may be to maintain levels of dNTPs that are sufficient for HIV-2 replication. 
These studies suggest that replication of HIV-2 may be more dependent on the 
availability of dNTPs compared to HIV-1. Thus, small molecules that lower the 
dNTP pools, including RNRIs, may be more effective against HIV-2 than HIV-1. 
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RNRIs used in combination with NRTIs may be able to slow the 
development of HIV-2 drug resistance since, unlike HIV-1, HIV-2 RT cannot 
excise NRTIs and instead relies only on the exclusion of dNTP analogs to 
develop NRTI drug resistance (Boyer et al., 2012; Boyer et al., 2006; Ntemgwa et 
al., 2009). The combination of an RNRI that depletes the corresponding dNTP 
pool of an NRTI analog could enhance NRTI incorporation during HIV-2 
chemotherapy. Since HIV-2 RT can only exclude NRTIs, but not excise NRTIs 
that have already been incorporated, the combination of NRTIs and RNRIs 
during the treatment of HIV-2 infected individuals may delay the emergence of 
HIV-2 drug resistance. 
Despite a more limited drug repertoire for the treatment of HIV-2 infection 
due to natural occurring resistance polymorphisms (Gottlieb et al., 2009; MacNeil 
et al., 2007; Menendez-Arias & Alvarez, 2014; Rodes et al., 2000; Smith et al., 
2009; Witvrouw et al., 2004), and the potential promise of RNRIs to selectively 
inhibit HIV-2 replication, no studies have examined the efficacy of RNRIs against 
HIV-2. Accordingly, in this study, we examined the ability of RNRIs gemcitabine, 
resveratrol, and clofarabine to inhibit replication of HIV-2. The ability of these 
RNRIs to inhibit HIV-1 and HIV-2 replication were compared, and time of addition 
assays were performed to examine at what point in the viral life cycle the RNRIs 
were acting. 
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Materials and Methods 
In all of these assays, HIV-1 and HIV-2 plasmids containing an identical 
dual fluorescent reporter cassette, pNL43-MIG and pROD10-MIG, respectively, 
were used to produce vector virus stocks. The construction of pNL43-MIG and 
the methods used to produce and titer viral stocks have been described 
previously (Rawson et al., 2013). The molecular clone pROD10-MIG was created 
by inserting the mCherry gene from pHIV-1 MIG (Rawson et al., 2013) in place of 
the mouse heat stable antigen from pROD10-HIG (Rawson et al. submitted), as 
follows. First, a fragment of pHIV-2 HIG spanning env, hsa, and IRES was 
amplified and ligated into pGEM-T (Promega Corp; Madison, WI).  Next, the 
resulting construct and pHIV-1 MIG were digested with BamHI and AvrII (New 
England Biolabs; Ipswich, MA). The appropriate fragments were purified and 
ligated together using T4 DNA ligase (New England Biolabs), thus swapping hsa 
for mCherry within the pGEM-T subclone. Last, the pGEM-T subclone and pHIV- 
2 HIG were digested with PmlI, which cleaves within env and IRES. The vector 
was treated with Antarctic Phosphatase (New England Biolabs), and the 
appropriate fragments were ligated together using T4 DNA ligase. Similar to 
pNL43-MIG, pROD10-MIG expresses mCherry and EGFP and all viral proteins 
except Env and Nef. 
For drug treatment experiments, VSV-G pseudotyped HIV-1 and HIV-2 
vector virus stocks produced in HEK 293T cells obtained from ATCC (Manassas, 
VA) were used to infect 10,000 Magi-U373-CXCR4CEM cells/well in a 96-well 
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plate format that had been pre-treated for 2 hours with increasing concentrations 
of drugs or with vehicle, DMSO. The small molecules tested in these experiments 
were zidovudine, tenofovir, nevirapine, raltegravir, 5-azacytidine, clofarabine, 
resveratrol and gemcitabine. Zidovudine, tenofovir, nevirapine and raltegravir and 
the Magi-U373-CXCR4CEM cell line were all obtained from the NIH AIDS Reagent 
Program. Resveratrol was obtained from Sigma Aldrich (St Louis, MO), 5- 
azacytidine and gemcitabine were obtained from Carbosynth (Compton, UK). 
Clofarabine was obtained either from the National Cancer Institute or from Alfa 
Aesar (Ward Hill, MA). Flow cytometry detecting mCherry and EGFP was used to 
quantify infectivity generated from the dose responses using these drugs, and 
EC50 values were calculated in GraphPad Prism6 (San Diego, California, USA). 
GraphPad was also used to determine if HIV-1 and HIV-2 EC50 values were 
statistically different from one another, as indicated in Table 1. 
Results and Discussion 
Table 2-1 reports the EC50 values calculated for each member of an eight 
drug panel from at least four different independent experiments. Dose response 
curves and EC50 values were obtained for each independent experiment using 
nonlinear regression models that generated unambiguous EC50 values for both 
HIV-1 and HIV-2 and that gave acceptable fits in a combined replicates test. 
These replicate EC50 values were subjected to an unpaired two-tailed t-test to 
generate a compiled EC50 value for each drug and to compare whether the EC50 
values differed for HIV-1 and HIV-2 (Mamotte et al., 1999). Our results show that 
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all compounds tested with the exception of nevirapine possessed potent anti- 
HIV-1 and HIV-2 activity. Consistent with previous publications, nevirapine 
inhibited HIV-1, but not HIV-2 replication (Balzarini, 2004). Resveratrol, 
clofarabine, and 5-azacytidine showed statistically different EC50 values, as 
indicated by a p value of 0.05 or less. In contrast, zidovudine, tenofovir and 
raltegravir did not show any significant differences in their comparative HIV-1 and 
HIV-2 EC50 values, in agreement with previously published reports (Smith et al., 
2008; Smith et al., 2011; Witvrouw et al., 2004). Notably, this report 
demonstrates for the first time both the anti-HIV-1 and HIV-2 activity of 
clofarabine. 
Our lab has previously reported the toxicity of 5-azacytidine (Dapp et al., 
2009), resveratrol, gemcitabine (Clouser et al., 2012a; Clouser et al., 2010; 
Rawson et al., 2013), and clofarabine (Beach et al, unpublished data) using the 
same cell line as reported here. Based on our previous reported toxicity data, it is 
unlikely that the antiviral activity shown here can be attributed to cytotoxic effects. 
In support of this, microscopic inspection of the cells as well as forward and side 
scatter by flow cytometric analysis did not reveal any evidence of increased cell 
death or abnormalities with any of the drug treatments reported here. Although 
we have not previously reported the cytoxicity of nevirapine, our finding that 
nevirapine inhibits HIV-1 but not HIV-2 suggests that the antiviral activity is 
specific and not due to cytotoxicity. 
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The results showing a similar antiviral efficacy for zidovudine, tenofovir, 
and raltegravir, but not for nevirapine, correlate with previously reported findings 
comparing anti-HIV-1 and anti-HIV-2 activity (Andreatta et al., 2013; Roquebert 
et al., 2008; Witvrouw et al., 2004). It was found that HIV-2 is more sensitive to 
the RNRIs gemcitabine, clofarabine, and resveratrol than HIV-1 by approximately 
2.04 fold, 3.49 fold, or 4.21 fold, respectively. These findings support the 
hypothesis that HIV-2 would be more sensitive to RNRIs when compared to HIV- 
1. Notably, only resveratrol and clofarabine showed a statistically significant 
decrease in the EC50 value in these assays, but all RNRIs tested showed a trend 
of inhibiting HIV-2 more than HIV-1. Interestingly, we also found HIV-2 was 
approximately 1.4 fold more sensitive than HIV-1 to inhibition with 5-azacytidine. 
The antiviral mechanism of action of 5-azacytidine has been reported to be the 
lethal mutagenesis of HIV-1 (Dapp et al., 2009). These findings suggest further 
study of RNRIs and lethal mutagens against HIV-2 may be warranted. 
After characterizing the drug dose responses in our panel, we performed 
vector virus time-of-addition (TOA) assays to identify the phase of the HIV-1 and 
HIV-2 life cycle that was inhibited by these compounds. Infections and the 
analysis of infectivity were performed using the same methods as described for 
the dose response assays described above, except that rather than pre-treating 
with drugs for 2 hours before infection, drugs were added immediately at the time 
of infection, or at varying time points thereafter. Cell culture media was changed 
24 hours after each drug treatment for every time point. All drugs were given at 
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concentrations that extinguished viral infectivity in the dose-response assays. 
The infectivity observed at the 0 hour time point for each drug was subtracted 
and infectivity was subsequently normalized to the no drug control at the 24 h 
time point. We performed each TOA three independent times. In TOA assays, 
the last time point a drug consistently stops HIV replication correlates with the 
step of the HIV life cycle the drug inhibits (Daelemans et al., 2011). Based on the 
timing of the HIV retroviral life cycle, we conducted our vector virus TOA assays 
to measure the ability of drugs to inhibit HIV replication through the integration 
phase of the viral life cycle. 
Based on previous literature, we a priori defined any drugs that stopped 
inhibiting replication at or before 1 hour as entry or fusion inhibitors; any drugs 
that stopped inhibiting replication from 3 to 4 hours were defined as reverse 
transcriptase inhibitors; and any drugs that inhibited replication after 6 hours 
were defined as integrase inhibitors (Daelemans et al., 2011). It was 
hypothesized that depending on when RNRIs depleted dNTP pools, RNRI- 
mediated inhibition of infectivity could map after fusion but before traditionally 
reported RT times. This hypothesis was based on the fact that RNRIs inhibit HIV 
RT indirectly, by inhibiting dNTP pools, rather than by directly causing chain 
termination or the steric hindrance of RT polymerization, like NRTIs and NNRTIs, 
respectively. Similar to previous publications, the time of drug inhibition was 
qualitatively defined in the assays in this study as the time point after which 
infectivity was consistently detected above baseline (Daelemans et al., 2011). 
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The results indicate RNRIs inhibit HIV-1 and HIV-2 during the reverse 
transcription phase of the viral life cycle (Figures 2-1 and 2-2, respectively). 
Interestingly, gemcitabine and resveratrol lose their antiviral efficacy at earlier 
time points than clofarabine, but within a similar time frame as defined by the 
bounds of the loss of inhibition of tenofovir, zidovudine, and, for HIV-1, 
nevirapine. In this assay, we observed FDA approved RT inhibitors exert their 
inhibitory effects between 2 and 4 hours. This suggests that in this assay 
inhibition from 2 to 4 hours should be interpreted as selective for the RT phase of 
the HIV life cycle. The breadth of this window could reflect different timing of 
cellular uptake and phosphorylation of nucleoside analogs in the Magi-U373- 
CXCR4CEM line. For the RNR inhibitors, it is also possible that these variations 
reflect differences in the timing, longevity, and efficiency by which they inhibit 
RNR. Additional studies would be needed to investigate these mechanistic 
possibilities. 
The timing of the inhibition of RT was distinguishable from the inhibition of 
integrase in the assay. The integrase inhibitor raltegravir inhibited HIV -1 through 
6 hours and HIV-2 through 8 hours, the penultimate time points tested. In the 
drug panel, only raltegravir inhibited HIV-1 or -2 replication at 6-8 hours - no 
other drug inhibited HIV-1 replication past 4 hours or HIV-2 replication past 6 
hours. 
Overall, these studies indicate the antiviral activity of the RNRIs 
gemcitabine, resveratrol, and clofarabine as well as the mutagen 5-azacytidine is 
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selective for the reverse transcription phase of the HIV life cycle. The data also 
show that the drugs were comparable in their inhibition of HIV-1 and HIV-2 in all 
cases except for resveratrol, clofarabine, and 5-azacytidine, which showed 
greater anti-viral activity against HIV-2, and nevirapine, which showed greater 
anti-viral activity against HIV-1. These results do not reveal a mechanism 
responsible for the increased potency of RNRIs against HIV-2. Recent reports, 
however, demonstrate that HIV-2, but not HIV-1 must degrade the dNTP pool 
regulator SAMHD1 for successful infection of macrophages and other myeloid 
cells, which are known to have extremely low dNTP pools (Diamond et al., 2004; 
Kim et al., 2012). The increased dNTP pools that arise through Vpx-induced 
SAMHD1 degradation have been hypothesized to be responsible for the rapid 
emergence  of NRTI drug resistance in HIV-2 infected individuals (Amie et al., 
2013a). It is tempting to speculate that RNRI treatment of HIV-2 infection could 
decrease dNTP pool levels below the Km of HIV-2 RT in macrophages, resting 
CD4 T cells, and dendritic cells, disrupting the progression of HIV-related 
pathogenesis and slowing the pace of the evolution of NRTI drug resistance in 
patients. Future studies will be needed to investigate the ability of RNRIs to 
inhibit HIV-2 replication in these cell types. RNRI’s may hold unique potential for 
use as antiretroviral agents for HIV-2 infection - a forgotten virus with few 
effective treatment options. 
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Table 2-1 EC50 values of drugs under study for HIV-1 and HIV-2 infection. 
alog(inhibitor) vs. normalized response was used to determine EC  . 50 
blog(inhibitor) vs. response (three parameters) was used to determine EC  . 50 
clog response (inhibitor) vs. response (variable slope) was used to determine EC . 50 
dCurve fitting was performed using log inhibitor vs normalized response. If the goodness of fit was 
not appropriate as determined by the replicates test and residuals, the curves were fit using either 
the log inhibitor vs response or log inhibitor vs response (variable slope) as indicated. 
eEC values for each replicate were used to perform an unpaired two-tailed t-test to determine 50 
differences between HIV-1 and HIV-2. Experiments were performed in parallel with HIV-1 and 
HIV-2 for each drug at least 4 times. 
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Drug 
 
HIV-1 EC50 
(µM) 
[95% confidence 
interval]d 
HIV2 EC50 
(µM) 
[95% confidence 
interval]d 
Significant 
difference in 
EC50 values 
(p < 0.05)e 
EC50 ratio 
HIV-1/HIV-2 
 
gemcitabinea 
 
1.3 × 10-3 
[2.28 x 10-4 - 2.81 x 10-3] 
 
6.36 × 10-4 
[3.95 × 10-4 -1.67 × 10-3] 
 
N 
 
2.04 
 
clofarabineb 
 
1.12 × 10-1 
[3.06 × 10-2 -1.94 × 10-1] 
 
3.21 × 10-2 
[9.52 × 10-4 -63.2 × 10-2] 
 
Y 
 
3.78 
 
resveratrolc 
 
25.6 
[20.1-31.0] 
 
6.08 
[4.49-7.68] 
 
Y 
 
4.21 
 
5-azacytidinec 
 
20.2 
[18.7-21.8] 
 
14.5 
[10.3-18.8] 
 
Y 
 
1.39 
 
raltegravirb 
 
1.72 × 10-3 
[8.47 × 10-4 - 4.30 × 10-3] 
 
1.85 × 10-3 
[4.43 × 10-3 -4.15 × 10-3] 
 
N 
 
0.93 
 
tenofovirb 
 
1.9 × 10-1 
[49.8 × 10-2 -3.31 × 10-1] 
 
1.30 × 10-1 
[1.40 × 10-2 -2.73 × 10-1] 
 
N 
 
1.46 
 
zidovudinea 
 
3.67× 10-2 
[2.72 × 10-2 -4.62 × 10-2] 
 
4.46 × 10-2 
[2.73 × 10-2 -6.19 × 10-2] 
 
N 
 
0.823 
 
nevirapinea 
 
6.2 
[5.31-7.12] 
 
No activity 
 
- 
 
- 
 
 
Figure 2-1 HIV-1 Time of Drug Addition Assay. Magi cells seeded into 96 well plates were 
infected with VSV-G pseudotyped HIV-1 vector virus. At 0, 1, 2, 3, 4, 6, and 24 hours post 
infection, infected cells were treated with DMSO or with inhibitory concentrations of clofarabine 
(Clo), zidovudine (AZT), tenofovir (TFV), resveratrol (Res), raltegravir (Ral), nevirapine (NVP), 5- 
azacytidine (5AZC), gemcitabine (Gem). Infections were performed three times, background 
infectivity at the 0 hour time point was subtracted, and infectivity for drug treatments was 
normalized to DMSO infectivity at the 24 hour time point. Values represent the averages of three 
independent experiments, with each treatment at each time point treated in duplicate. Infectivity 
was normalized to no drug, which was set at 100 at the 24 h time point. The measured no drug 
infectivity average value at 24 h was 46%. 
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Figure 2-2. HIV-2 Time of Drug Addition Assay. Magi cells seeded into 96 well plates were 
infected with VSV-G pseudotyped HIV-2 vector virus. At 0, 1, 2, 3, 4, 6, 8 and 24 hours post 
infection, infected cells were treated with DMSO or with inhibitory concentrations of clofarabine 
(Clo), zidovudine (AZT), tenofovir (TFV), resveratrol (Res), raltegravir (Ral), 5-azacytidine (5AZC), 
or gemcitabine (Gem). Infections were performed three times, background infectivity at the           
0 hour time point was subtracted, and infectivity for drug treatments was normalized to DMSO 
infectivity at the 24 hour time point. Values represent the averages of three independent 
experiments, with each treatment at each time point treated in duplicate. Infectivity was 
normalized to no drug, which was set at 100 at the 24 h time point. The measured no drug 
infectivity average value at 24 h was 55%. 
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Chapter 3 
Investigation of the antiretroviral mechanism of action of clofarabine 
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Abstract 
The deoxyadenosine analog and ribonucleotide reductase inhibitor (RNRI) 
2-Chloro-9-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)-9H-purin-6-amine, or 
clofarabine, is FDA approved to treat refractory pediatric acute lymphoblastic 
leukemia. In this study, we show for the first time that clofarabine also has anti- 
HIV-1 activity. Our studies show the selectivity index of clofarabine to be 3349 in 
Magi-U373-CXCR4CEM cells and 35.9 in CEM-GFP cells. Further characterization 
of clofarabine’s anti-HIV-1 activity in the Magi-U373-CXCR4CEM cell line revealed 
an increase in HIV-1 mutational loads when compared to no drug controls. At 
clofarabine’s EC50 concentration, we observed a 2.03 fold increase in HIV-1 
mutant frequency. Sequencing of the proviral DNA revealed significant 
clofarabine-associated differences in the HIV-1 mutation spectra. In particular, 
clofarabine-treatment was associated with significantly higher G-to-A transition 
mutations, in the context of G-to-A hypermutated sequences. Analysis of dNTP 
pools revealed that at non-toxic, antiviral concentrations, clofarabine significantly 
depleted dATP and dGTP nucleotide pools. Our data demonstrates that 
clofarabine exerts potent anti-HIV-1 activity, increases HIV-1 mutation, and 
depletes purine dNTP pools in the Magi-U373-CXCR4CEM cell line. 
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Introduction 
For over three decades, the HIV/AIDS epidemic has been one of the 
world’s most pressing global public health challenges. Currently there are six 
FDA-approved classes of anti-HIV-1 medications that allow people living with HIV 
who receive timely treatment to expect a near normal lifespan (Johnson et al., 
2013), (Nakagawa et al., 2012). In the past three years, the success of treatment 
as prevention (Anglemyer et al., 2013) and pre-exposure prophylaxis (Celum, 
2011) have also shown these same medications are effective at blocking the 
transmission and acquisition of HIV-1. These findings have led to the 
recommendation that all HIV-1 infected people be placed onto early treatment, 
both to benefit their own health and to protect the health of the community 
(Cohen et al., 2013). 
Since the first anti-HIV-1 medications entered clinical development, drug 
resistance associated with mutations in the HIV-1 genome has been known to 
reduce the effectiveness of HIV-1 treatment (St Clair et al., 1991). Given the 
important role antiretroviral drugs play in both HIV-1 treatment and prevention, 
drug resistance presents an increasing threat not only against the health of HIV 
infected individuals, but also in the community level fight against HIV. The CDC 
reports cases of newly transmitted HIV-1 drug resistance are on the rise in the 
USA (Taylor et al., 2013). As increasing numbers of people living with HIV 
access treatment, community viral loads will decrease. Reduction in community 
HIV-1 viral load has been shown to reduce population level transmission rates of 
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HIV-1 (Das et al., 2010). As more people living with HIV attain undetectable viral 
loads, drug resistance associated treatment failures may increasingly drive HIV-1 
transmission. To keep up with the future of the HIV/AIDS epidemic, tactical 
pharmacological innovations in treatment and prevention are warranted. In 
particular, the development of drugs that could re-sensitize drug resistant 
mutants to existing HIV medications could play a crucial role under the new 
public health paradigm of HIV-1 treatment as both treatment and prevention. 
The history of antiretroviral drug development reveals that in the context of 
the current HIV-1 epidemic, ribonucleotide reductase (RNR) may be strategic to 
revisit as an anti-HIV-1 drug target. The RNRIs hydroxyurea (Lori et al., 1994), 
resveratrol (Heredia et al., 2000), (Clouser et al., 2012a), (Rawson et al., 2013), 
and gemcitabine (Clouser et al., 2010) have independent anti-HIV-1 activity in 
cell culture. Recently, knockdown of the small subunit of RNR, RRM2, has also 
been shown to be antiviral, demonstrating that RNR is a valid, anti-HIV-1 target 
(Allouch et al., 2013). Notably, the ribonucleotide reductase inhibitors (RNRI)s 
hydroxyurea (HU) and resveratrol (RV) can re-sensitize NRTI-resistant HIV-1 
mutants to NRTI treatment (Balzarini, 2000), (Heredia et al., 2000), (Heredia et 
al., 2013). 
The ability of RNRIs to inhibit HIV-1 replication and to resensitize drug 
resistant HIV-1 variants has been associated with their ability to deplete dNTP 
pools (Balzarini, 2000). The relationship between low dNTP pool levels and 
inhibition of HIV infection has long been known (Gao et al., 1993), (Johns & Gao, 
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1998). The naturally low dNTP pools in macrophages helps limit HIV-1 replication 
in these cells (Diamond et al., 2004), (Allouch et al., 2013). The antiviral 
mechanism of SAMHD1 has been attributed to its ability to deplete dNTP pools 
(Amie et al., 2013a), (Kim et al., 2012). 
In this study, the RNRI clofarabine was investigated to determine if the 
drug possessed anti-HIV-1 activity. Clofarabine triphosphate (Clo-TP) is a well 
known allosteric inhibitor of the regulatory subunit of ribonucleotide reductase, 
RRM1 (Aye et al., 2012; Aye & Stubbe, 2011; Chang & Cheng, 1980). 
Clofarabine, therefore, is a prodrug that needs activation first to its 
monophosphate form (Clo-MP), then to its diphosphate and triphosphate forms 
by monophosphate and diphosphate kinases, respectively, before it can inhibit 
RNR (Lotfi et al., 1999; Nagai et al., 2011; Xie & Plunkett, 1995). Clofarabine is a 
deoxyadenosine analog that is FDA approved to treat refractory or relapsed 
pediatric acute lymphoblastic leukemia (Faderl et al., 2005). We chose to study 
clofarabine because of its high oral availability (Jacoby et al., 2014), its 
comparatively long half life (Bonate et al., 2004), its high stability, and its low 
prevalence of associated toxic metabolites (Bonate et al., 2011), when compared 
to other RNRIs. Our results show that at non-toxic antiviral concentrations, 
clofarabine depletes dATP pools by ten fold and dGTP pools by 3.7 fold and 
increases the mutant frequency of HIV-1 in Magi-U373-CXCR4CEM cells by two 
fold. Recently, our lab has also reported the anti-HIV-1 activity of the RNRIs 
resveratrol and gemcitabine is associated with an increase in the mutant 
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frequency of HIV-1 (Rawson et al., 2013). This study demonstrates for the first 
time the anti-HIV-1 activity of clofarabine. It is also the first study that reports 
simultaneously the effect of an RNRI on dNTP pools, HIV-1 mutation frequency, 
and HIV-1 proviral mutation spectra in the same cell culture model. Ongoing 
studies will be performed to characterize the molecular mechanism of clofarabine 
against HIV-1 and will investigate its ability to resensitize HIV-1 drug resistant 
mutants to approved anti-HIV-1 medications. RNRIs with improved anti-viral 
efficacy and reduced toxicity may bring new promise to the fight against the 
acquisition and transmission of HIV-1 drug resistance. 
Results 
Clofarabine Has Potent Anti-HIV-1 Activity 
To determine if clofarabine had anti-HIV activity, we performed both single 
cycle vector virus and spreading HIV-1 live virus in the presence or absence of 
clofarabine. To perform vector virus experiments, we used the recently reported 
dual-fluorescent reporter plasmid, pNL43-MIG (Rawson et al., 2013). The data 
shows that clofarabine has an EC50 value of 854 nM, with a 95% confidence 
interval of 723 nM to 1.01 µM (Figure 3-1). This EC50 places clofarabine among 
the RNRI’s with the most potent anti-HIV activity in tissue culture. Gemcitabine, 
resveratrol, and hydroxyurea have previously reported EC50 values in the low 
nanomolar, low micromolar and low millimolar concentrations, respectively 
(Clouser et al., 2010; Lori et al., 1994; Rawson et al., 2013). 
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Figure 3-1 Clofarabine Inhibits HIV-1 in a Vector Virus Model. Magi-U373-CXCR4CEM cells 
pre-treated with increasing concentrations of clofarabine or with vehicle (DMSO) were infected 
with pNL43-MIG. Flow cytometry was used to monitor viral infectivity. Infections were normalized 
to the DMSO control, and the normalized values were entered into GraphPad Prism 6 and log 
transformed. The EC50 values were calculated using the log(inhibitor) vs. normalized response - 
variable slope nonlinear regression test. Replicates analysis confirmed the appropriateness of the 
statistical test. The experiment was performed three independent times. Error bars represent 
standard deviation (SD). The EC50 of clofarabine was 854 nM, with 95% CI values of 723 nM to 
1010 nM. 
Clofarabine’s low EC50 value in the vector virus model inspired us to 
determine its efficacy in a spreading HIV-1 infection. Briefly, we infected CEM- 
GFP cells with the infectious HIV-1 molecular clone, NL4-3, at an MOI of 0.01. 
Dose responses obtained from these experiments revealed the antiviral activity 
of clofarabine in a spreading HIV-1 infection to appear to be more potent, with an 
EC50 of 15.8 nM (Appendix I). Collectively, these results demonstrate clofarabine 
has a powerful antiviral effect in cell culture that appears in line not only with the 
50 
 
potency of other RNRI’s, but also with FDA approved anti-HIV-1 medications 
(Parkin & Schapiro, 2004). 
Anti-HIV-1 Effects of Clofarabine are not Explained by Cytotoxicity 
Clofarabine, like gemcitabine and hydroxyurea, is an anti-cancer drug that 
is used clinically for its cytotoxic effect (Jeha et al., 2004). One obvious potential 
explanation that could spuriously account for clofarabine’s anti-viral activity in our 
cell culture models is cytotoxicity. To examine if the observed antiviral activity 
could be due to cytoxicity, we examined the effects of clofarabine on cell toxicity 
using an ATP-based cell viability assay. The data shows that the concentrations 
of clofarabine that exert antiviral activity were not toxic to the cells. The TC50 of 
clofarabine in MAGI-U373-CXCR4CEM cells was 2.86 mM, (Figure 3-2). The 
TC50 of clofarabine in the CEM-GFP cell line was 567 nM (Figure 3-2). 
Figure 3-2 Clofarabine Has Limited Toxicity in the Magi-U373-CXCR4CEM and CemGFP Cell 
Lines. Toxicity analysis of clofarabine was performed using the Promega CellTiter-Glo Luminescent Cell 
Viability Assay Kit according to the manufacturer’s instructions. All samples were normalized to the no drug 
control. The TC50 value of clofarabine in the Magi cell line was 2.86 mM, with a 95% CI of 640.2 µM to 12.8 
mM. The TC50 value of clofarabine in the CEMGFP line was 567 nM, with a 95% CI of 172 nM to 1.87 µM. 
For Magi-U373-CXCR4CEM (Figure 2A) and for CemGFP (Figure 2B) cells, experiments were performed 
three independent times. The error bars represent the standard deviation. 
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A comparison of the EC50 and TC50 values of clofarabine indicates that the 
anti-HIV-1 efficacy of clofarabine cannot be explained by cytotoxicity at the doses 
used in our model systems. The selectivity index of clofarabine in the Magi-U373- 
CXCR4CEM cell line is 3.35 x 103 and 35.9 in the CEM-GFP line. 
Clofarabine Depletes dATP and dGTP Pools in Magi-U373-CXCR4CEM Cells 
Since clorafabine is an RNRI, we examined whether its anti-HIV activity 
corresponded to alterations in the dNTP pools. (Lotfi et al., 1999; Parker et al., 
1991; Xie & Plunkett, 1996).To examine the effects of clofarabine on dNTP 
pools, a dual ion-pair LCMS-MS method was used. Three million Magi-U373- 
CXCR4CEM cells were treated with 0.5 or 5.0 µM clofarabine for 3, 6, or 24 hours 
before harvesting the cells and extracting dNTP’s. The results show that at 3 and 
6 hours post treatment, both the low and high clofarabine concentrations 
significantly depleted dATP and dGTP, but not dCTP or TTP pools (Figure 3-3). 
Time of drug addition experiments in cells and in patients have shown in 
one round of replication, reverse transcription ends approximately 4.5 to 6 hours 
post initial infection with HIV-1 (Daelemans et al., 2011; Murray et al., 2011). 
Therefore, our dNTP pool studies show that clofarabine can deplete dNTP pools 
during the same time frame of the reverse transcription phase of the HIV-1 life 
cycle in the Magi-U373-CXCR4CEM cell line. 
The dNTP pool analysis also showed the inhibition by clofarabine of dATP 
and dGTP pools is relatively long lived. At 24 hours, clofarabine continued to 
effectively inhibit dATP and dGTP pools, implicating Clo-TP was still present 
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within these cells. This finding agrees with patient studies where over 50% of 
Clo-TP was found to be present in leukemic cells 24 hours after initial clofarabine 
infusion (Gandhi et al., 2003). Interestingly, clofarabine treatment after 24 hours 
also led to a significant increase in TTP pools. The dCTP pools, which previously 
had exhibited a non-significant downward trend, were unaffected. These findings 
indicate that at antiviral concentrations, clofarabine treatment was not toxic in 
Magi-U373-CXCR4CEM cells, an increase in dNTP pools would be inconsistent 
with drug induced cell death or cytostaticity. These findings, combined with 
previous reports from clinical trials, also provide promising evidence that Clo-TP 
may persist long enough to be compatible with once daily dosing schedules for 
treatment of HIV-1, though more extensive testing in patients would be needed. 
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Figure 3-3 Clofarabine Significantly Depletes dATP and dGTP Pools in Magi-U373- 
CXCR4CEM cells. Magi-U373-CXCR4CEM cells were treated with DMSO, 0.5 µM or 5 µM 
clofarabine for 3, 6, or 24 hours before being harvested for dual ion pair LCMS-MS dNTP pool 
analysis. The mean and the standard deviation were calculated and plotted after normalization to 
the internal standard. A one-way ANOVA with Tukey's post-test was used to assess differences 
among all treatment groups. Clofarabine significantly depleted deoxypurine but not 
deoxypyrimidine nucleotide pools. * P < 0.05, **P <.01, ***P < 0.001. 
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Anti-HIV-1 Activity of Clofarabine Correlates with an Increase in HIV-1 
Mutant Frequency 
Many groups have reported even small imbalances in dNTP pools to be 
mutagenic, both for viruses and for cells (Ahluwalia & Schaaper, 2013; Julias & 
Pathak, 1998; Kumar et al., 2011; Rampazzo et al., 2010). Imbalances in dNTP 
pool have been found to affect the fidelity of HIV-1 reverse transcriptase 
(Bebenek et al., 1992). RNRIs both alone (Rawson et al., 2013) and in 
combination with mutagens (Clouser et al., 2010) have been reported to enhance 
HIV-1 mutant frequency. Since the HIV-1 mutation frequency is sensitive to 
changes in cellular dNTP pools and clofarabine imbalances deoxypurine pools, it 
the ability of clofarabine treatment to increase mutant frequency was next 
examined. 
A dual fluorescent reporter vector virus system was used to assess whether 
clofarabine increased HIV-1 mutant frequency. The vector virus system enables 
both the infectivity and mutant frequency values to be assessed from the same 
samples. The results demonstrated a correlation between loss of infectivity and 
an increase in mutant frequency (Figure 3-4). At concentrations nearly 
extinguishing HIV-1 infection, in one round of replication, clofarabine increased 
HIV-1 mutant frequency by over 7 fold. At its EC50 concentration, the mutant 
frequency value observed in the presence of clofarabine was 2.03 times higher 
than the no drug control. These values place the HIV-1 mutation frequency 
values in one round of replication in the presence of clofarabine above the 
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reported values using the same assay for resveratrol and gemcitabine, and even 
above the values observed for KP-1212, a compound that had entered clinical 
trials as a lethal mutagen of HIV-1 (Rawson et al., 2013). 
Figure 3-4 Clofarabine Increases the Mutant Frequency of HIV-1. To determine mutant 
frequency, cells were pre-treated with increasing concentrations of clofarabine or with DMSO, 
then infected with pNL43-MIG. Dual color flow cytometry was performed and mutant frequency 
was calculated as described in the Materials and Methods. At the EC50 concentration, 
clofarabine’s mutant frequency was 2.03 times higher than the DMSO vehicle control, with lower 
and upper 95% confidence interval values of 1.32 fold and 2.74 fold, respectively. The data are 
from three independent experiments, and error bars represent the standard deviation. 
The ability of clofarabine to enhance HIV-1 mutant frequency raises a 
concern that at non-cytotoxic levels, clofarabine may also act as a mutagen to 
cells. In its FDA regulatory approval package, clofarabine is reported not to show 
any activity in the bacterial Ames test. Regulatory agencies use Ames test results 
as a surrogate to indicate that a drug does not increase toxic frameshift or point 
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mutations (Li et al., 1991a) in the human genome. Results from a mammalian 
mutation detecting HGPRT assay referenced in (Clouser et al., 2010) show that 
neither non-toxic, antiviral concentrations of gemcitabine alone, nor of the 
synergistically mutagenic combination of decitabine and gemcitabine, increased 
the mutation frequency of mammalian cellular DNA. While this manuscript does 
not report the ability of clofarabine to modulate the mutation of cellular DNA, 
clofarabine’s lack of toxicity at antiviral concentrations, combined with its lack of 
signal in the Ames test indicates that it is unlikely to be mutagenic to the human 
genome. 
Clofarabine is Associated with Increased Mutation in HIV-1 Proviral DNA 
The increase in mutant frequency combined with the decrease in dATP and 
dGTPs suggest that clofarabine may affect the mutation spectra of HIV. To 
determine if clofarabine affected the mutant spectra of HIV-1, proviral DNA was 
sequenced from infected cells treated with clofarabine or DMSO. Sequencing of 
the egfp gene revealed that clofarabine treatment increased G-to-A transition 
mutations, in the context of G-to-A hypermutated sequences (Figure 6). When 
all mutations were included, clofarabine treatment was associated with 
statistically higher G-to-A, T-to-C, and C-to-T transition mutations. No significant 
differences were found for A-to-G or for transversion mutations. 
When G-to-A mutations in the context of G-to-A hypermutated sequences 
were removed from the mutational analysis, no significant differences between 
the mutant spectra of clofarabine and DMSO treatment, with the exception of an 
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overall statistically higher number of combined transversions detected in 
clofarabine when compared to DMSO treated proviral sequences. No single 
transversion mutation, however, was found to be significantly higher in 
clofarabine treated cells (Appendix IV). 
Unlike in past studies (Clouser et al., 2010; Holtz & Mansky, 2013; Rawson et 
al., 2013), sorting of single positive fluorescent infected cells to enrich for 
mutations was not done in this study. Infected cells positive for only one marker 
gene could be less likely to contain extensively hypermutated sequences. 
Viruses with higher numbers of G-to-A mutations may have both marker genes 
knocked out, resulting in cells that actually contain hypermutated viruses, but 
which appear uninfected. Though a rare event, G-to-A hypermutation has a large 
impact on mutant spectra because of how many mutations accumulate in one 
sequence. 
Figure 3-5 Mutant Spectra of Clofarabine vs. DMSO. Cells were treated with 5 µM clofarabine 
or with DMSO and infected with DNaseI treated pNL4-3-MIG. Genomic DNA was extracted and 
DpnI treated. The efgp sequence was PCR amplified and ligated into a bacterial cloning vector, 
Sanger sequenced and analyzed for mutations. For DMSO, 83 mutations were detected from 132 
sequences, and for clofarabine,107 mutations were detected from 69 sequences. Sequences with 
duplicated mutations were only counted once. All G-to-A transition mutations in hypermutated 
sequences are included in this analysis. 
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Table 3-1 Mutant Spectra Statistical Analysis. 
aMutations recovered from 69 clofarabine treated sequences and 132 DMSO treated sequences 
were analyzed using Fisher’s exact test. The mutations analyzed included G-to-A mutations from 
hypermutated sequences. 
bAll mutation types analyzed except A-to-G and total compiled transversion mutations were 
significantly different between the two treatments. * P <0.05, **P < 0.01, ***P < 0.001. 
Discussion 
Clofarabine, a ribonucleotide reductase inhibitor (RNRI), is FDA approved to 
treat refractory pediatric acute lymphoblastic leukemia. Previously, other FDA- 
approved RNRIs have been found to exert anti-HIV-1 activity. These RNRIs have 
been shown to change the mutant spectra and increase the mutation frequency 
of HIV-1(Clouser et al., 2010; Rawson et al., 2013). The mechanism responsible 
for these changes, however, has not yet been thoroughly established. In this 
study, we report that clofarabine has anti-HIV-1 activity associated with increases 
in HIV-1 mutant frequency and an increase in G-to-A transition mutations in the 
context of G-to-A hypermutation. 
Hypermutated G-to-A retroviral sequences have been reported since the early 
days of the HIV-1 epidemic, both in patients and in cell culture (Li et al., 1991b; 
Mansky, 1996). In the early 2000’s, members of the APOBEC3 protein family 
were reported to cause this G-to-A hypermutation (Sheehy et al., 2002; Zheng et 
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al., 2004). Today, APOBEC3G, APOBEC3F, APOBEC3DE and APOBEC3H 
have all been found to be packaged into HIV-1 viral particles, leading to the G-to- 
A hypermutation that restricts HIV-1(Hultquist et al., 2011). Given the prevailing 
view that APOBEC3 proteins must be packaged into retroviral particles to cause 
G-to-A hypermutation, it is not clear why in a single cycle vector virus assay, 
different target cell types would have different rates of G-to-A hypermutation 
(Holtz & Mansky, 2013), or why clofarabine treatment would be associated with 
more G-to-A hypermutation than DMSO treatment in target cells. Target cell 
activity has been reported for APOBEC3C, (Bourara et al., 2007), which is known 
to be expressed in Magi-U373-CXCR4CEM cells. However, this activity was not 
found to cause extensive hypermutation (Bourara et al., 2007), nor did 
APOBEC3C expression correlate with the different levels of hypermutation found 
in different target cell types (Holtz & Mansky, 2013). 
Interestingly, at least one paper has proposed a relationship between 
APOBEC3G activity and deoxynucleotide pools (Plesa et al., 2007). These 
authors proposed that in resting CD4 cells, APOBEC3G and APOBEC3F could 
be partially responsible for the slower RT kinetics observed in these cells, which 
the addition of deoxynucleosides helps overcome. Recent reports of the 
SAMHD1 restriction factor have shown that fluctuations in dNTP pools can affect 
target cell susceptibility to HIV-1 infection. SAMHD1 has been reported to restrict 
HIV at the step of reverse transcription (Laguette et al., 2011) by depleting dNTP 
pools below the concentrations necessary to sustain reverse transcription 
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(Goldstone et al., 2011). Vpx degrades SAMHD1 and can counteract the 
restriction factor’s ability to block HIV-1 infection in monocyte derived 
macrophages (MDM’s) (Goldstone et al., 2011; Hrecka et al., 2011; Laguette et 
al., 2011; Lahouassa et al., 2012). It has been shown that when increasing 
amounts of exogenous dNTP’s are added to SAMHD1 containing MDM’s 
infected with Vpx containing HIV-1 VLPs, the ability of SAMHD1 to restrict HIV-1 
is depleted in a dose responsive fashion (Lahouassa et al., 2012). HU treatment 
can block the recovery of HIV-1 infectivity associated with Vpx, demonstrating 
that RNR inhibition prevents the cell from synthesizing the dNTP’s that would 
allow for recovery of reverse transcription and viral infectivity (Lahouassa et al., 
2012). These results, as well as studies showing variations in the concentration 
of cellular dNTPs affect the kinetics of reverse transcription (Diamond et al., 
2004), strongly suggest that dNTPs in the cytoplasm of the infected cell can gain 
access to the retroviral reverse transcription complex. 
The mutant spectra results from our studies may suggest some insight into 
the relationship between dNTP pool levels and APOBEC3 restriction factor 
activity. Our results show that clofarabine depletes dNTP pools during the time 
frame reverse transcription would occur in the Magi-U373-CXCR4CEM cells. 
Depletions in dNTP pools due to RNRI treatment have been shown to slow down 
the kinetics of HIV-1 reverse transcription (Lori et al., 1994). The portions of HIV- 
1 viral DNA that remain single stranded the longest have been shown to have 
more G-to-A hypermutation (Chelico et al., 2006). APOBEC3G has also been 
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reported to slow down the kinetics of HIV-1 reverse transcription utilizing a 
deamination-independent mechanism, which would result in the enhancement of 
its deamination-dependent antiviral restriction (Adolph et al., 2013; Iwatani et al., 
2007). Taken together, these studies implicate a relationship between dNTP pool 
levels, RT kinetics and APOBEC3 restriction, whereby depleted dNTP pools 
would lead to slower HIV RT kinetics and therefore be associated with more 
extensive APOBEC3 induced G-to-A hypermutation in target cells. This model is 
also consistent with Plesa et al's observation that APOBEC3G and APOBEC3F 
have opposite effects on RT kinetics in resting CD cells as deoxynucleoside 
addition. This model assumes target cell dNTP's readily diffuse into the retroviral 
core during reverse transcription. 
Ongoing work is needed to characterize clofarabine’s ability to deplete viral 
DNA products and affect RT kinetics. It is possible that in addition to dNTP pool 
depletion, any decrease in viral DNA we observe could be due to Clo-TP’s ability 
to be incorporated and act as a mutagen or as a non-canonical DNA chain 
terminator. Our mutant spectra results did not reveal a specific mutational 
signature for clofarabine, suggesting that Clo-TP, if incorporated, does not cause 
a specific mutation type. No other studies have ever suggested that Clo-TP 
would have mutagenic properties upon incorporation into DNA, and the Ames 
test results reported in the FDA approval package for clofarabine indicates that 
clofarabine is not mutagenic in a prokaryotic cellular system. In contrast, Clo-TP 
has been shown to compete with dATP and to inhibit DNA polymerase alpha 
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after its incorporation into DNA (Parker et al., 1991), suggesting that at least one 
human DNA polymerase recognizes Clo-TP as a dATP molecule. The finding 
that heavily mutated EGFP sequences can be recovered from clofarabine treated 
cells, however, argues against viral DNA chain termination being the sole 
mechanism responsible for the anti-HIV-1 activity of clofarabine. 
Overall, these studies demonstrate that clofarabine possesses potent anti- 
HIV-1 activity, and that this antiviral activity is associated with an increase in viral 
mutational burden. Future studies will continue to characterize the molecular 
mechanism of the anti-HIV-1 activity of clofarabine. In particular, these studies 
will investigate if HIV-1 RT can incorporate clofarabine triphosphate as well as 
the comparative contributions reductions in viral DNA synthesis and lethal 
mutagenesis make to clofarabine’s anti-HIV effects. 
Materials and Methods 
Cell Lines, Plasmids and Reagents 
The Magi-U373-CXCR4CEM and human embryonic kidney (HEK 293T) cell 
lines were obtained from the American Type Culture Collection (ATCC, 
Manassas, VA). CEMGFP cells, the HIV-1 molecular clone pNL4-3, and the 
pCXCR4 plasmids were obtained from the NIH AIDS Reagent Program, Division 
of AIDS, NIAID, NIH. pHCMV-G was a kind gift from J. Burns (University of 
California, San Diego). The HIV-1 vector plasmid encoding EGFP-IRES- 
mCherry, also known as pNL43-MIG, has been previously described (Rawson et 
al., 2013). The CellTiter-Glo cell proliferation kit was purchased from Promega 
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(Madison, WI). Clofarabine was obtained from the National Cancer Institute and 
from Alfa Aesar (Ward Hill, MA). 5-iodo-dCTP was purchased from TriLink 
BioTechnologies (San Diego, CA). Dimethylsulfoxide (DMSO) was from 
ThermoFisher Scientific (Waltham, MA). For transfections, poly-L-lysine was from 
Newcomer Supply (Middleton, WI), and polyethylenimine (PEI) was from 
Polysciences, Inc. (Warrington, PA). DNase was from Invitrogen (Carlsbad, CA). 
DpnI was from New England Biolabs (Ipswich, MA). The genomic DNA from 
Magi-U373-CXCRCEM cells was extracted using Zymo Research Corporation’s 
Zymobead Genomic DNA Extraction Kit (Irvine, CA). Miniprep kits and Platinum 
PCR Supermix were from Invitrogen (Carslbad, CA). Sanger sequencing was 
performed by Functional Biosciences (Madison, WI) using the T7 Forward 
Promoter sequencing primer, TAA TAC GAC TCA CTA TAG GG. PCR products 
were ligated into PGEM-T using Promega’s (Madison, WI) PGEM-T Kit. 
Cell Culture 
Magi-U373-CXCR4CEM cells were maintained in Dulbecco’s modified 
Eagle’s Medium (DMEM) (Life Technologies; Carlsbad, CA) containing 10% 
HyClone FetalClone III (FC3) serum from Thermo Scientific (Waltham, MA), 1% 
penicillin/ streptomycin from Invitrogen (Carlsbad, CA), 1 µg/ml puromycin, 0.2 
mg/ml neomycin and 0.1 mg/mL hygromycin. HEK 293T cells were maintained in 
DMEM containing 10% FC3 and 1% penicillin/streptomycin. CEMGFP cells were 
maintained in Roswell Park Memorial Institute 1640 medium (RPMI) (Mediatech, 
Inc.; Manassas, VA) containing 10% FC3 and 1 mg/mL neomycin. Cell lines were 
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split every 2-7 days as needed using trypsin from Invitrogen. When splitting, cell 
lines were washed using Dulbecco’s Phosphate Buffered Saline (PBS). All cells 
were maintained at 37°C in 5% CO2. 
Production of Virus Stocks 
Virus was produced by co-transfecting either pNL43-MIG and pHCMV-G 
or pNL43-MIG and pCXCR4 via the PEI method (Boussif et al., 1995). PEI 
stocks were prepared at 1 mg/mL by dissolving PEI in water, adjusting the pH to 
7.0, and filtering through a 0.2 µM filter. On the day before transfection, 4 million 
293T cells were plated onto 10 cm dishes that were pre-coated with 1x poly-L- 
lysine. Twenty-four hours later, the media was removed and 5 mL of fresh 293T 
media were added. One mL of serum-free and antibiotic free DMEM containing 
10 µg pNL4-3 MIG + 1 µg of envelope protein (either pHCMV-G or pCXCR4) + 
33 µL 1 mg/mL PEI that had incubated for 15-20 minutes at room temperature 
was added dropwise to each plate.  Five hours after transfection, the media was 
replaced, and virus was collected 24 hours later by spinning down the 
supernatant for 5 minutes at 1200g, following by filtration through a 0.22 µm filter. 
Viral stocks were aliquoted and frozen at -80°C. 
Viral stocks were titered in U373-MAGI-CXCR4CEM cells. The day before 
infection, 1.5 X 104 cells were plated in a 96 well dish. The next day the media 
was replaced and increasing amounts of either HIV1 vector virus was added, in 
biological duplicate. The media was replaced again 24 hours post-infection and 
cells were collected 48 hours post-infection for analysis by flow cytometry. 
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Drug Treatments and Vector Virus Infection 
The day before infection, Magi-U373-CXCR4CEM cells (3.125 X 104 per 
well) were seeded onto 24 well plates. The next day, the medium was removed, 
and 1 µL of drug or DMSO and 499 µL of medium was added to each well. Each 
treatment was performed in duplicate. Two hours after drug treatment, HIV-1 
CXCR4 vector virus diluted in Magi medium was added to each well for a final 
volume of 1 mL. Twenty-four hours after infection, the medium was changed. 
Twenty-four hours after the medium change, cells were trypsinized, centrifuged 
for 5 minutes at 1200 x g and the pellet was resuspended in 2% FC3 in 
Dulbecco’s PBS. Flow cytometry to detect EGFP and MCherry was performed 
the same day. The resulting flow data was analyzed using FlowJo version 7.6.1 
(Ashland, Oregon). 
The infectivity observed for each drug concentration was calculated by 
averaging the biological replicates in Excel (Microsoft; Redmond Washington). 
Afterwards, for each experiment, the average infectivity for each drug 
concentration was normalized to DMSO (no drug) infectivity, by dividing the 
average percent infection observed for each drug concentration by the average 
percent infection observed for DMSO treatment. DMSO treatment was then set 
to one and all values were multiplied by 100 to obtain normalized percentages. 
The experiments were performed on three different days with three independent 
viral stocks. The EC50 value for clofarabine was determined by entering the 
normalized infectivity for the three independent experiments into GraphPad 
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Prism and plotting the infectivity against the log-transformed drug concentrations. 
The nonlinear regression model of log(inhibitor) vs. response - variable slope 
(four parameters) was used to calculated clofarabine's EC50 value and the 95% 
confidence interval. Replicates analysis indicated that this was the best fit 
nonlinear regression model to use to analyze this data. 
Mutant Frequency Analysis 
Mutant frequency values were determined by adding the total number of 
EGFP+/mCherry- and EGFP-/mCherry+ cells and dividing by the total number of 
infected EGFP+/mCherry-, EGFP-/mCherry+ and EGFP+/mCherry+ cells. These 
values were then normalized to the DMSO no-drug control mutant frequency 
values and entered into GraphPad Prism. A linear regression was performed and 
plotted with the EC 95% confidence intervals (CI). The mutant frequency was 
calculated at the EC50 of clofarabine, along with the 95% CI. Only experiments 
where the no-drug infection was 13% to 25% were used to calculate the mutant 
frequency. 
Live Virus Infection and Drug Treatments 
In 24 well plates, 100,000 CEMGFP cells/well were infected at an MOI of 
.01 in a spreading infection using four independent HIV-1 NL4-3 viral stocks that 
had been previously titered using the classical method of Reed and Muench. In 
duplicate, wells were treated with DMSO or varying concentrations of clofarabine. 
Every 2 days, cells were removed for flow cytometry and fresh media and drug 
was added. Infection levels were monitored by quantifying the percentage of cells 
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that were EGFP positive, using flow cytometry. The experiment was run until the 
infectivity level peaked, which typically occurred between 8 and 12 days. The 
EC50 value for clofarabine was calculated as describe above in the, “Drug 
Treatments and Vector Virus Infection,” using the infectivity levels reported 
during the peak of viral infection. 
Cytotoxicity Analysis 
The cytotoxicity of clofarabine was examined using the CellTiter-Glo 
Luminescent Cell Viability Assay kit from Promega, according to the 
manufacturer's instructions. U373-MAGI-CXCR4CEM cells (5,000/well), 293T cells 
(5,000/well), or CEMGFP cells (50,000/well) were plated in a 96-well dish 24 
hours prior to drug treatment. Cells were treated with clofarabine for 24 hours 
and 24 hours later, cellular proliferation (an indication of the level of cytotoxicity) 
was analyzed using an Orion microplate luminometer from Berthold Detection 
Systems (Huntsville, AL). Dimethyl sulfoxide (DMSO) was used as a control for 
the no-drug-treated cells.  For each experiment, values obtained from wells 
without cells were subtracted from all samples and the clofarabine-treated values 
were normalized against the DMSO treated values of the appropriate volumes 
that were used to add drug. The normalized values from each experiment were 
then entered into GraphPad Prism version 6.0 (GraphPad Software, Inc.; La 
Jolla, CA), drug concentrations were log transformed, and a nonlinear regression 
analysis of log(inhibitor) vs. three parameters was performed to generate IC50 
values and 95% confidence intervals. Replicates tests indicated that this model 
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generated an appropriate EC50 fit for the data. The data represents a total of 3 
experiments for all cell lines analyzed. 
Sequencing of Proviral DNA 
Magi-U373-CXCR4CEM cells were plated 24 hours before treatment with 5 
µM clofarabine or with an equivalent volume of DMSO. Two hours after drug 
treatment, cells were infected with DNase-treated pNL43-MIG. To confirm that 
the clofarabine was working as expected, infectivity controls were performed in 
parallel. The anti-viral activity of clofarabine was confirmed by flow cytometry 48 
hours later. Twenty-four hours after infection, genomic DNA from the clofarabine- 
treated or DMSO-treated cells was isolated using Zymo Research Corporation’s 
ZymoBead DNA Extraction Kit (Irvine, CA). The extracted DNA was treated with 
DpnI from New England Biolabs (Ipswich, MA). Using the genomic DNA as a 
template, PCR was performed to amplify the EGFP gene, using Invitrogen’s 
Platinum PCR Supermix (Carlsbad, CA). The primers used in the PCR reaction 
were 5’-CAAGCGTATTCAACAAGG-3’ and 5’-GCAATACAGCAGCTAACAATG- 
3’. The PCR fragment containing EGFP was ligated into PGEM-T (Promega; 
Madison, WI) and transformed into chemically competent DH5α E. coli. Individual 
colonies were grown, plasmid DNA was recovered using the Invitrogen 
PureLink® Quick Plasmid Miniprep Kit (Carlsbad, CA), and the EGFP gene was 
sequenced using Sanger sequencing. Sequences were aligned to the reference 
and mutations identified using Lasergene (DNASTAR, Inc., Madison, WI). Any 
sequences with the same mutations were assumed to be identical, and therefore 
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only mutations from one of these sequences were counted. Sequencing was 
performed on genomic DNA extracted from three different infections using three 
different pNL43-MIG VSV-G stocks. In total, 83 unique mutations from 133 
DMSO-treated EGFP sequences and 107 unique mutations from 69 clofarabine- 
treated EGFP sequences were obtained. Statistical differences between the 
mutant spectra of the clofarabine-treated cells and the DMSO-treated cells were 
determined using Fisher’s exact test. 
dNTP Pool Analysis 
The day before dNTP pools were extracted, 3 million Magi-U373- 
CXCR4CEM cells were plated in a 10 cm2 dish. Cells were then treated with 
DMSO, 0.5 µM clofarabine or 5.0 µM clofarabine for 3, 6 or 24 hours. Each plate 
was trypsinized, washed in PBS to remove dead cells, and cells were counted 
using a hemocytometer. Three million cells from each treatment were 
resuspended in 200 µL of 65% ice cold methanol containing 10 µM 5'-Iodo- 
2'dCTP from TriLink BioTechnologies (San Diego, CA), then lysed by vigorous 
vortexing. The mixture was stored at -20Cº overnight to precipitate proteins. The 
next day, samples were centrifuged at 14,000g for 10 minutes. The supernatant 
was collected and the methanol was removed by speed vacuuming. 
The lyophilized samples were submitted for dual ion pair high performance 
liquid chromatography-tandem mass spectrometry (LCMS-MS). LCMS-MS was 
performed using an Agilent 1260 HPLC. A 150 mm – 3.9 mm Waters XTerraMS 
C-18 column (5 µM) was used to separate the nucleotides, with a mobile phase 
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of 5 mM hexylamine containing 0.5% diethylamine in water (pH 10, adjusted with 
acetic acid; mobile phase A) and 50/50 water/acetonitrile (mobile phase B). The 
flow rate was 0.3 ml/min. A linear gradient of 0% to 30% of mobile phase B was 
used to elute analytes over 30 minutes. Mobile phase B (95%) was used to clean 
the column for 3 minutes and the column was then re-equilibrated for 15 minutes 
with mobile phase A (100%). 
The Agilent 1260 HPLC was coupled to an AB SCIEX QTRAP 5500 mass 
spectrometer. The samples were run using an electrospray source operating in 
positive/negative polarity switching mode, utilizing the following settings: curtain 
gas: 20;CAD gas: medium; ion spray voltage: 4500; temperature: 600°C; gas1: 
45; and gas 2: 45. Multiple reaction monitoring (MRM) was used to analyze 
deoxynucleotides and internal standard (IS), using the parameters listed in 
Appendix II. The fragmentation sites for each dNTP are depicted in Figure II-1. 
Each LCMS-MS run was exported into MultiQuant (AB SCIEX), to calculate peak 
areas. Figure II-2A of Appendix II illustrates representative chromatograms for 
dATP, dCTP, dTTP, and IS from a typical run. Due to the overlap of ATP and 
dGTP peaks, a less efficient mass transition was used to monitor dGTP than for 
the other dNTP pools. Comparatively, therefore, dGTP has a much lower peak 
height than the other dNTP peaks in our assay. For ease of analysis, the dGTP 
peak is illustrated in a separate chromatogram, in Figure II-2B of Appendix II. 
In Figure 4, the dNTP pool levels are expressed as integrated peak areas 
normalized to the internal standard. For quality control purposes, data from dNTP 
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experiments was only used if the standard of variance for the internal standard 
was less than 20%. The mean and the standard error of the mean (SEM) were 
calculated and plotted for the IS normalized data. One-way analysis of variance 
(ANOVA) with Tukey's post-test was used to assess differences among all 
treatment groups. A P value of <0.05 was considered statistically significant, as 
indicated by an asterisk. Two asterisks indicate a P-value of less than .01. Three 
asterisks indicate a P-value of less than .001. 
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Chapter 4 
General summary and future directions 
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Since 1981, the human immunodeficiency virus (HIV) has been reported 
to infect seventy-five million people and has claimed the lives of over thirty-six 
million people worldwide (UNAIDS, 2013), making HIV/AIDS one of the most 
devastating global infectious disease epidemics the world has ever seen. Though 
the advent of highly active antiretroviral therapy (HAART) has extended the lives 
of many HIV infected individuals, there remains a pressing need for the 
development of new drugs. HIV drug resistance, both primary and transmitted, 
undermines the effectiveness of existing antiviral treatments. Worse, some viral 
types and subtypes have naturally occurring resistance polymorphisms that 
make the use of some or all classes of anti-HIV drugs partially or totally 
ineffective. 
Unlike HIV-1, HIV-2 is resistant to the first generation NNRTIs (Witvrouw 
et al., 2004). HIV-2 is also partially resistant to some protease inhibitors and to 
enfuvirtide (Campbell-Yesufu & Gandhi, 2011; Witvrouw et al., 2004). The 
restricted treatment options for HIV-2 infection and the comparative lack of study 
of HIV-2 present a serious barrier for the effective treatment of HIV-2 infected 
individuals. In this dissertation, the anti-HIV-2 activity of ribonucleotide reductase 
inhibitors was explored, to determine if members of this drug class could expand 
the treatment options for HIV-2. It was hypothesized that because HIV-2 appears 
to require higher cellular dNTP concentrations to complete reverse transcription 
compared to HIV-1, lower doses of RNRIs could be used to inhibit this virus. 
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The findings of these dissertation studies reveal the RNRIs clofarabine 
and resveratrol as well as the mutagen 5-azacytidine exert comparatively more 
potent antiviral activity against HIV-2 than HIV-1 during reverse transcription. The 
results also indicate gemcitabine is at least as effective at inhibiting HIV-2 
replication as HIV-1 replication. Notably, these studies report for the first time the 
anti-HIV1 and HIV-2 activity of clofarabine. 
The remainder of this dissertation presents the first investigation of the 
anti-HIV-1 mechanism of action of clofarabine. To date, mechanistic studies have 
revealed the antiviral activity of clofarabine is associated with an increase in HIV- 
1 mutational burden and the depletion of dATP and dGTP pools in a vector virus 
assay. This dissertation, while reporting the correlation between increased 
mutational burden and the antiviral effects of clofarabine, does not contain a 
definitive analysis of the relative contribution of increased mutation compared to 
other potential anti-HIV mechanisms of action. Chapter 1 discusses how a 
reduction in one or more dNTP pools often leads both to increased viral mutation 
and to decreases in viral DNA synthesis. Reductions in viral DNA synthesis may 
complicate mechanistic studies that seek to evaluate the exclusive contribution of 
enhanced mutagenesis to reductions in HIV infectivity. 
Although the studies in this dissertation do indicate that clofarabine 
enhances HIV-1 mutagenesis, they do not prove conclusively that lethal 
mutagenesis is the primary mechanism of action of clofarabine against HIV-1. 
Several other mechanisms could also contribute to the antiviral effect of 
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clofarabine. Based on clofarabine's observed ability to reduce dNTP pools in the 
Magi-U373CEM cell line, it is likely clofarabine's RNRI activity accounts for at least 
part of its antiviral mechanism. A reduction in dNTPs could reduce infectivity in 
several ways. For example, a reduction in dNTP concentrations below the Km of 
RT for dNTPs would likely reduce viral DNA synthesis (Diamond et al., 2004). 
This mechanism could be examined through qPCR. Second, alterations in 
dNTPs have been shown to increase the mutation frequency of HIV, thereby 
leading to a reduction in infectivity (Mansky, 2003). The results in this dissertation 
are consistent with enhanced mutagenesis contributing to the antiviral activity of 
clofarabine. 
Besides acting as a RNRI, clofarabine may also inhibit HIV infectivity 
through direct incorporation into the viral genome after its conversion to the 
triphosphorylated form. Such incorporation could lead to a pause or delay or non- 
canonical termination of reverse  transcription, which would lead to reduced 
infectivity. Studies with cellular DNA polymerases indicate multiple polymerases 
can incorporate both clofarabine triphosphate and clofarabine monophosphate, 
and that this incorporation limits DNA elongation (Parker et al., 1991; Xie & 
Plunkett, 1995; Xie & Plunkett, 1996). In vitro RT incorporation assays could be 
used to examine this potential mechanism. 
Other experiments that could contribute to investigations of whether 
increased mutation or decreased viral DNA synthesis were primarily responsible 
for the antiviral activity of clofarabine include selecting for clofarabine resistant 
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HIV-1 and determining if RNR mutants resistant to clofarabine inhibition still 
retained antiviral activity (Aye & Stubbe, 2011). 
The successful selection of HIV-1 drug resistance mutants in cell culture 
can be used to examine the mechanisms of action of antiviral drugs. If 
clofarabine’s primary mechanism of action is to act as a non-canonical DNA 
chain terminator due to drug incorporation, resistance mutations would likely be 
similar to mutations that confer resistance to NRTIs used to treat HIV-1. If, 
however, clofarabine acts primarily as a viral mutagen, resistance may be difficult 
to select. However, such a resistance mutation would be expected to increase 
the fidelity of RT. 
Experiments investigating the impact of RNR mutants resistant to 
clofarabine on HIV infectivity would test if RNR inhibition is required for 
clofarabine’s antiviral effect. Interestingly, the D57N mutant of RRM1 is resistant 
to allosteric inhibition by clofarabine triphosphate (Aye & Stubbe, 2011). If the 
antiviral activity of clofarabine persisted even without the drug's ability to 
decrease dNTP pools, this finding would suggest inhibition of viral DNA synthesis 
would be clofarabine's primary mode of action against HIV. 
Overall, this dissertation contains the first description of the anti-HIV-1 and 
HIV-2 activity of clofarabine. More experiments are needed to fully characterize 
the mechanism of clofarabine’s antiviral activity. Future pre-clinical testing in 
humanized mouse models, non-human primate models as well as eventual 
clinical trials in human subjects would be necessary to evaluate the feasibility of 
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the clinical translation of clofarabine for use as an antiretroviral agent. To date, 
neither the long-term side effects nor the antiretroviral efficacy of low-dose 
clofarabine have been studied. The development, optimization, and approval of 
RNRIs for use against HIV could provide life-saving salvage therapy options for 
patients living with HIV-1 and HIV-2. Additionally, RNRIs like clofarabine could 
likely be used to boost the efficacy of NRTI-containing HAART regimens for 
patients harboring NRTI drug resistant HIV infections. If drug resistance 
mutations affect the efficacy of PrEP, RNRIs could also be potentially used to 
boost the efficacy of PrEP, though this application would require extensive future 
investigation. 
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Appendix I 
Live virus activity of clofarabine 
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The anti-HIV-1 activity of clofarabine was analyzed in CEMGFP cells by 
Michael Dapp, as described in the, “Live virus infection and drug treatment,” 
section of the Materials and Methods of Chapter 3. This work revealed 
clofarabine possessed an EC50 of 15.8 nM, with a 95% confidence interval 
ranging from 9.92 to 25.2 nM, in a live HIV-1 immortalized t-cell line model 
system (Figure I-1). 
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Figure I-1 Clofarabine inhibits HIV-1 in a Spreading Infection. CEMGFP cells were infected 
with pNL4-3 at an MOI of .01 and treated in duplicate with concentrations of clofarabine ranging 
from 300 pM to 30 nM. Every two days, cells were split, and fresh drug and media were added. 
The EC50 values were calculated from the peak day of infection for each experiment (n=4). 
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Additionally, I performed spreading infections with pNL4-3 using an 
identical method as described in the Materials and Methods of Chapter 3, with 
the exception that an MOI of .05 instead of .01 was used. The results from the 
replication kinetics from these spreading infections are shown in Figure I-2. The 
EC50 value of clofarabine was calculated to be 9.475 nM, placing this value very 
close to the bottom range of the 95% confidence interval defined by Michael 
Dapp. 
Figure I-2 Clofarabine inhibits HIV-1 in a Spreading Infection. CEMGFP cells were infected 
with pNL4-3 at an MOI of .05 and treated in duplicate with concentrations of clofarabine ranging 
from 300 pM to 30 nM. Every two days, cells were split, and fresh drug and media were added. 
The EC50 values were calculated from the peak day of infection (n=1). 
A comparison of the EC50 value of 15.8 nM for clofarabine that was 
calculated by Michael Dapp and the TC50 concentration of 567 nM that I 
determined in the CEMGFP cell line demonstrates that clofarabine possesses a 
selectivity index of 35.9 in this cell line. This selectivity index (SI) is lower than 
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the SI of FDA approved anti-HIV-1 drugs, but higher than the SI of many anti- 
cancer drugs. Further work will need to be done to determine if the toxicity profile 
of clofarabine warrants additional investigation of clofarabine as a therapeutic 
agent to treat HIV-1 and HIV-2 infection. 
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Appendix II 
dNTP pool methods 
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Figure II-1 and Figure II-2 below depict the dNTP fragmentation patterns 
and sample chromatograms of the different dNTP pools analyzed in the LSMS- 
MS experiments. The parameters of the LCMS-MS experiments were designed 
and performed by Dr. Benjamin Duckworth of the Center for Drug Design at the 
University of Minnesota, with input from Dr. Steven Patterson. The samples 
analyzed by LCMS-MS were prepared by Lauren Beach. 
Figure II-1 Schematic of dNTP Fragmentation Pattern from LCMS-MS Experiments. 
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Figure II-2. Representative chromatograms of dNTP pool peaks from LCMS-MS assay. II2.A 
shows peaks from dATP, dCTP, TTP, and IS pools. II2.B shows the dGTP pool peak using a 
different scale bar, because of the much less robust detection of the dGTP pool in our assay. 
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Appendix III 
Clofarabine vs. DMSO comparative mutant spectra analysis without G-to-A 
hypermutants included 
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To determine the effect of the G to A hypermutations on the overall mutant 
spectra of HIV exposed to clofarabine or DMSO (refer to Chapter 3, Table 1 and 
Figure 3.5), the G-to-A mutations from EGFP sequences with 2 or more G-to-A 
mutations were removed from the mutant spectra analysis. The Fisher’s Exact 
Test was used to compare the different types of transition mutations or compiled 
transversion mutations. After removal of the G-to-A mutants in the context of 
hypermutated sequences, no significant differences in transition mutations 
remained (Table III-1). Total transversion mutations were comparatively higher 
for the EGFP sequences exposed to clofarabine than to DMSO. However, no 
significant differences were detected in the 8 possible transversion mutations 
when comparing genomes exposed to clofarabine or DMSO. 
Table III-1 Statistical Analysis of Clofarabine and DMSO Mutant Spectra with G-to-A 
Mutations from G-to-A Hypermutated Sequences Removed. 
aFisher’s Exact test was used to compare different mutation types from egfp HIV-1 proviral 
sequences exposed to clofarabine or DMSO, without considering G-to-A transition mutations 
found in G-to-A hypermutated sequences. *P<0.05 
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Figure III-1. Comparative Mutant Spectra of Clofarabine vs. DMSO, without G-to-A 
Hypermutated Sequences. VSV-G pseudotyped pNL4-3 infected cells were treated with 5 µM 
clofarabine or with DMSO. Genomic DNA was extracted and the egfp gene was amplified and 
Sanger sequencing was performed. Mutations were compiled, and the G-to-A transition mutations 
from sequences containing 2 or more G-to-A mutations were removed from the analysis. For 
DMSO, 132 sequences were analyzed, yielding 54 mutations and for clofarabine, 69 sequences 
were analyzed, yielding 32 mutations. The figure depicts the percent of each type of mutation that 
was identified. 
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Appendix IV 
The late phase effects of clofarabine 
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Clofarabine is FDA approved for the intended use of treating relapsed or 
refractory acute pediatric leukemia (Gandhi & Plunkett, 2006). The well- 
established cytotoxic molecular mechanisms of action of clofarabine include 
direct inhibition of DNA synthesis and the inhibition of RNR as reviewed in 
(Bonate et al., 2006; Zhenchuk et al., 2009). Translating clofarabine’s anti-cancer 
effects to its potential anti-HIV applications indicates these mechanisms would 
inhibit the early (i.e. pre-integration) phase of the HIV-1 life cycle, assuming an 
anti-viral selectivity index greater than 1. Chapter 3 of this dissertation 
demonstrates that decreases in the infectivity of clofarabine are accompanied by 
an increase in HIV-1 mutant frequency. 
At high concentrations, clofarabine has also been reported to contribute to 
cytotoxicity by being incorporated into RNA and interfering with translation 
(Bonate et al., 2006). The ability of clofarabine to inhibit the late phase of HIV-1 
replication without cytotoxicity was previously unexplored. Accordingly, a single 
cycle producer cell assay was used to test the ability of clofarabine to inhibit the 
post-integration, or “late phase” of HIV-1 replication. The method was optimized 
to eliminate drug carryover concerns, to ensure that the assay would not be 
influenced by any early-phase inhibitory effects of the drugs tested in the assay. 
Briefly, 205,000 293T cells per well were plated onto poly-L-lysine-coated 
12 well tissue culture dishes. The next day, cells were transduced with pNL43- 
MIG and a plasmid containing the VSV envelop protein, pHCMV-G, using the PEI 
method. Five hours after transduction, the media was changed and increasing 
110 
 
amounts of clofarabine, nelfinavir, zidovudine or DMSO (vehicle) were added to 
each well. One day later, the media was changed to prevent drug carryover. After 
16 hours, the supernatant containing VSV-G pseudotyped HIV-1 vector virus was 
harvested and centrifuged to remove cellular debris. 293T cells were harvested 
and analyzed by flow cytometry to ensure equal transduction efficiencies. 
An equal ratio by volume of viral supernatant was added to a solution of 
4ºC 30% PEG/0.5M NaCl. The mixture was vortexed to homogeneity, stored at 
4ºC for 24 hours, and then centrifuged at maximum speed for 10 minutes. 
Following this, the supernatant was removed, the pellet was washed in a 50/50 
mixture of media and PEG solution and centrifuged at top speed for 10 minutes. 
The pellet was resuspended in 1.1 mL of media and incubated at 4ºC for 2 hours. 
The pellet was pipetted one time and used to infect 62,500 Magi-U373- 
CXCR4CEM cells/well of a 12-well plate that were plated the preceding day. 
Twenty four hours after infection, the media was changed, and 24 hours later, 
cells were harvested and flow cytometry was performed to determine HIV-1 
infectivity. Infectivity was normalized to DMSO and the data was analyzed in 
GraphPad as described in the “Drug Treatments and Vector Virus Infection,” 
section of Materials and Methods from Chapter 3, with the notable exception that, 
following a replicates analysis, the log(inhibitor) vs. three parameters was 
determined to be the best nonlinear regression model used to calculate EC50 
values for all drugs. The results from the producer cell experiments indicate that 
clofarabine has low micromolar anti-HIV-1 activity (Table IV-1 and Figure IV-1) 
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that maps to the late phase of the retroviral life cycle. 
Toxicity assays were performed to determine if toxicity of clofarabine in 
293T cells could account for clofarabine's late-phase anti-HIV-1 effect using, the 
CellTiter-Glo Luminescent Cell Viability Assay kit from Promega (Madison, WI), 
according to the manufacturer’s instructions and as outlined in the Materials and 
Methods of Chapter 3. The results from three independent experiments indicate 
that in the 293T cell line, clofarabine has a TC50  of 245.2 µM, with a 95% 
confidence interval of 41.9 µM to 1.44 mM (Table IV-1 and Figure IV-2). 
Clofarabine’s producer cell antiviral activity and its 293T cell toxicity result in a 
selectivity index (SI) of 36.1. This SI is much lower than the SI found for HIV-1 in 
the Magi-U373-CXCR4CEM cell line, but mirrors closely the anti-HIV-1 SI 
calculated for the CEMGFP cell line. 
Unlike the results from the EC50 and TC50 calculations for the CEMGFP 
and Magi-U373-CXCR4CEM cell lines, however, the confidence intervals for the 
EC50 and TC50 for the producer cell antiviral activity and toxicity experiments 
overlap. This finding suggests that at least some of clofarabine’s late-phase 
activity could be due to cytotoxicity in the 293T cell line, rather than to antiviral 
activity. 
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Figure IV-1 Late Phase Effects of Clofarabine, Nelfinavir and Zidovudine. Producer cell 
experiments were performed using a modified version of the vector virus target cell assay to 
determine if clofarabine possessed late phase anti-HIV-1 activity. The protease inhibitor nelfinavir 
(NFV) and the RT inhibitor zidovudine (AZT) were included as positive and negative controls, 
respectively. As expected, NFV showed potent anti-HIV-1 activity, while AZT did not show any. 
The error bars represent the standard error of the mean from three independent experiments. 
The EC50 values and 95% confidence intervals are reported in Table IV.1. 
Table IV-1 Late Phase EC50 Values of Clofarabine, Nelfinavir, and Zidovudine 
a This table reports the EC   and 95% confidence intervals for clofarabine, nelfinavir (NFV) and 50 
zidovudine (AZT) from the producer cell vector virus assay, calculated from three independent 
experiments. 
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Figure IV-2 Toxicity of Clofarabine in 293T Cells. Toxicity analysis of clofarabine was 
performed using the Promega CellTiter-Glo Luminescent Cell Viability Assay Kit according to the 
manufacturer’s instructions. All samples were normalized to the relative light units (RLUs) of the 
no drug DMSO control. The TC50 of clofarabine was determined to be 245 µM, with a confidence 
interval of 41.9 µM to 1.44 mM. Experiments were performed three independent times. Error bars 
represent the standard deviation. 
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Contributions 
This appendix is the attachment of a paper on which I was a co-author, "5,6- 
Dihydro-5-aza-2'-deoxycytidine potentiates the anti-HIV-1 activity of 
ribonucleotide reductase inhibitors" (Rawson et al., 2013). My contributions to 
this paper were that I cloned the mCherry-IRES-EGFP cassette, which Jonathan 
Rawson subsequently inserted into the HIV-1 molecular clone pNL4-3 
background, to make the single cycle HIV-1 vector, pNL43-MIG. Additionally, I 
performed the toxicity experiments shown in Figure 4 of the paper that 
demonstrate the reason 5 µM KP1212 decreases gemcitabine infectivity is not 
synergistic toxicity. 
Abstract 
The nucleoside analog 5,6-dihydro-5-aza-2’-deoxycytidine (KP-1212) has 
been investigated as a first-in-class lethal mutagen of human immunodeficiency 
virus type-1 (HIV-1).  Since a prodrug monotherapy did not reduce viral loads in 
Phase II clinical trials, we tested if ribonucleotide reductase inhibitors (RNRIs) 
combined with KP-1212 would improve antiviral activity.  KP-1212 potentiated the 
activity of gemcitabine and resveratrol and simultaneously increased the viral 
mutant frequency. G-to-C mutations predominated with the KP-1212-resveratrol 
combination. These observations represent the first demonstration of a mild anti- 
HIV-1 mutagen potentiating the antiretroviral activity of RNRIs and encourage the 
clinical translation of enhanced viral mutagenesis in treating HIV-1 infection. 
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Introduction 
Human immunodeficiency virus type-1 (HIV-1) infects about 34 million 
individuals globally and resulted in the deaths of 1.7 million in 2011 alone 
(UNAIDS, 2012). Despite great strides in antiretroviral therapy, current drugs are 
still limited by toxicity, cross-resistance, and the transmission of drug-resistant 
viral variants (Kim, 2013). HIV-1 has a high mutation rate (3 to 9 x 10-5 
mutations/base pair/cycle), (Gao et al., 2004; Mansky & Temin, 1995; O'Neil et 
al., 2002) and it has been postulated to replicate near the error threshold—a 
theoretical upper limit to the mutation rate beyond which genetic information 
cannot be maintained (Anderson et al., 2004; Dapp et al., 2013; Smith et al., 
2005). Thus, it is conceivable to exceed the error threshold with small molecule 
viral mutagens. This antiviral strategy, called lethal mutagenesis, was first 
investigated using mutagenic ribonucleoside analogs and RNA-damaging agents 
in poliovirus and vesicular stomatitis virus by Holland and colleagues in the 
1990s (Holland et al., 1990; Lee et al., 1997). It was later demonstrated in HIV-1 
using 5-hydroxy-2’-deoxycytidine, (Loeb et al., 1999) and subsequently explored 
in several other RNA viruses (Crotty et al., 2001; Crotty et al., 2000; Ruiz-Jarabo 
et al., 2003; Sierra et al., 2000). HIV-1 lethal mutagenesis has not been clinically 
exploited, but a prodrug of 5,6-dihydro-5-aza-2’-deoxycytidine (KP-1212) has 
advanced to clinical trials.  KP-1212 potently inhibited HIV-1 replication in culture 
(EC50 of ~10 nM) with low cellular, mitochondrial, and genome toxicities, as well 
as activity against both wildtype (wt) and drug resistant strains (Harris et al., 
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2005). KP-1212 was shown to induce primarily G-to-A and A-to-G (and to a 
lesser extent T-to-C and C-to-T) transition mutations within HIV-1. The prodrug of 
KP-1212 (KP-1461) was well tolerated in clinical trials, but was not effective in 
reducing viral loads despite adequate drug bioavailability (Clay et al., 2011; Hicks 
et al., 2013). Nonetheless, there was a detectable increase in the number of 
private mutations (i.e., those most likely to have occurred in the latest round of 
replication) and evidence of an altered mutation spectrum in clinical samples 
(Mullins et al., 2011). 
We have previously demonstrated that combinations of nucleoside 
analogs that act as viral mutagens and ribonucleotide reductase inhibitors 
(RNRIs) can result in synergistic decreases in viral infectivity (Clouser et al., 
2012; Clouser et al., 2010). Similarly, combining nucleoside reverse 
transcriptase inhibitors (NRTIs) with RNRIs results in potentiation of anti-HIV-1 
activity (Gao et al., 1994; Heredia et al., 2000; Lori et al., 1994). RNRIs likely 
have a threefold antiretroviral mechanism in such combinations: 1) inhibition of 
retroviral DNA synthesis via depletion of deoxynucleoside triphosphate (dNTP) 
pools; (Bianchi et al., 1986; Gao et al., 1993; Heinemann et al., 1990; Lori et al., 
1994) 2) many RNRIs do not inhibit synthesis of all four natural dNTPs equally, 
thus generating dNTP pool imbalances that increase the viral mutation rate; 
(Bianchi et al., 1994; Gao et al., 1994; Heinemann et al., 1990; Julias & Pathak, 
1998) and 3) decreases in cellular dNTP concentrations result in the upregulation 
of nucleotide kinases, leading to more efficient activation of nucleoside 
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analogues such as KP-1212 (Clouser et al., 2012; Clouser et al., 2010; Gao et 
al., 1994; Heredia et al., 2000; Lori et al., 1994). Given this, the combination of 
an RNRI with KP-1212 or a KP-1212 prodrug should result in potent inhibition of 
HIV-1 infectivity. 
We report here that while KP-1212 alone had minimal antiviral activity in 
our single round replication assay, it potentiated the activity of the RNRIs 
gemcitabine and resveratrol. The combination of KP-1212 with resveratrol, in 
particular, reduced the EC50 by 1.9-fold relative to resveratrol alone (i.e., from 
99.6 µM to 52.8 µM). The KP-1212-RNRI combinations led to corresponding 
increases in the viral mutant frequency in the absence of cell cytotoxicity relative 
to that of RNRIs alone. Taken together, these observations represent the first 
demonstration of a mild anti-HIV-1 mutagen having the ability to potentiate the 
antiretroviral activity of RNRIs.  These findings may improve the potential for 
clinical translation of KP-1212 in the treatment of HIV-1 infection. 
Results & discussion 
Development of an mCherry/GFP dual reporter HIV-1 vector 
In order to efficiently assess both HIV-1 infectivity and mutant frequency, 
we constructed a HIV-1 vector expressing two fluorescent proteins—mCherry 
and the green fluorescence protein (GFP) (Figure VI-1A). The resulting vector 
expresses all viral proteins except Env and Nef. Infectious vector virus was 
produced by trans-complementing with the vesicular stomatitis virus G protein 
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(VSV-G) via co-transfection with the vector virus plasmid. This strategy limits 
virus replication to a single cycle of replication. The utility of the construct for 
detecting drug-induced increases in virus mutant frequency was confirmed using 
5-azacytidine (5-AZC), a ribonucleoside analog previously shown to have 
antiretroviral activity against HIV-1 (Dapp et al., 2009). We found that treatment 
of target cells with 5-AZC reduced HIV-1 infectivity in a concentration-dependent 
manner, with an EC50 of 53.0 µM, comparable to the previously reported value 
of 57.0 µM (Figure VI-1B) (Dapp et al., 2009). We also observed a concentration- 
dependent elevation of the viral mutant frequency to a maximum of 19.8-fold 
relative to the no drug control, confirming previous findings with 5-AZC (Dapp et 
al., 2009). 
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Figure VI-1 Vector and assay design for rapid determination of HIV-1 infectivity and mutant 
frequency. (A) A dual-reporter (mCherry/GFP) HIV-1 vector was created and co-transfected with 
VSVG to produce infectious virus. Target cells were pre-incubated with drugs for 2 h before 
infection. Drug was removed 24 h post-infection and cells were collected 72 h post-infection for 
determination of infectivity and mutant frequency via flow cytometry, as described in Section 3.5. 
(B) The utility of the dual reporter HIV-1 vector for detecting alterations in infectivity and mutant 
frequency was validated using 5-azacytidine, a previously characterized potent mutagen of HIV- 
1.(Dapp et al., 2009) The data were normalized to the no drug (DMSO only) control and 
represent the mean ± sd of three independent experiments. 
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Individual effects of RNRIs and KP-1212 on HIV-1 infectivity & mutant 
frequency 
We initially combined KP-1212 at 100 µM with a panel of several anti- 
metabolites and found that KP-1212 potentiated the antiretroviral activity of 
gemcitabine (2’,2’-difluoro-2’-deoxycytidine, dFdC), resveratrol, and 
deferoxamine (data not shown). These three compounds have all been 
previously reported to have RNRI activity as well as antiretroviral activity, though 
inhibition of ribonucleotide reductase has not been clearly demonstrated to be 
their primary mechanism of action against HIV-1 (Baker et al., 1991; Clouser et 
al., 2012; Clouser et al., 2010; Fontecave et al., 1998; Georgiou et al., 2000; 
Heinemann et al., 1990; Heredia et al., 2000; Nyholm et al., 1993). Resveratrol, 
in particular, has been reported to interact with a wide variety of cellular targets in 
exerting its anti-inflammatory, anti-tumorigenic, and antiviral effects (Smoliga et 
al., 2011). We next characterized the individual effects of each compound on 
HIV-1 infectivity and mutant frequency. We found that gemcitabine, resveratrol, 
and deferoxamine all reduced HIV-1 infectivity (Figure VI-2A & Table VI-1) and 
elevated the viral mutant frequency in a concentration-dependent fashion (Figure 
VI-2B). 
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Figure VI-2 Effect of KP-1212 and RNRIs on HIV-1 infectivity and mutant frequency. Cells were 
infected with HIV-1 after being treated with KP-1212 or selected ribonucleotide reductase 
inhibitors (RNRIs) for 2 h. Treatments were concluded at 24 h post-infection by replacing the 
media, and cells were collected for analysis by flow cytometry at 72 h post-infection. The effects 
of the drugs on infectivity (A) and mutant frequency (B) were determined and normalized to the 
no drug control. The data shown are the mean ± sd of three independent experiments. 
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We observed that KP-1212 exerted only a mild antiviral effect alone, 
without concentration dependence in the concentration range of 5 to 200 µM 
(Figure VI-2A).  However, we observed a slight dose-dependent increase in 
mutant frequency (up to  ~1.6-fold) (Figure VI-2B).  Our observations using this 
assay are somewhat different than previous findings of KP-1212 being a potent 
inhibitor of HIV-1 replication (Harris et al., 2005). We tested multiple batches of 
KP-1212 to rule out the possibility of degradation of our liquid drug stocks (data 
not shown).  Additionally, 1H NMR and combustion analysis confirmed the purity 
and stability of KP-1212 in our hands (data not shown).  The differences in 
observed activity of KP-1212 may be due to the previous study using a very low 
multiplicity of infection (MOI), ranging from 1:1000 to 1:5000 (Harris et al., 2005). 
These authors found that higher MOIs led to higher EC50 values, and were not 
able to obtain a reproducible EC50 at MOIs of 1:300 or greater. In line with this, 
we used a much higher MOI (~1:3 to 1:5) and were unable to obtain an EC50. 
Additionally, the previous study used a different cell line (MT-2) and centrifuged 
the drug onto cells, potentially altering the uptake and/or phosphorylation of KP- 
1212.  Finally, the virus was likely not limited to a single round of replication, 
which potentially enhanced the observed effects of KP-1212. Despite the 
apparent discrepancies in antiretroviral potency, our findings are in relatively 
good agreement with the Phase II clinical trials on KP-1212, which found no 
clinically significant decline in viral loads but some evidence of mutagenicity 
126 
 
(increases in private mutations and altered mutation spectra) (Hicks et al., 2013; 
Mullins et al., 2011). 
KP-1212 potentiates the effects of RNRIs on HIV-1 infectivity & mutant 
frequency 
To further investigate the interaction between RNRIs and KP-1212, we 
combined a fixed low concentration of each RNRI with varying concentrations of 
KP-1212 (i.e., ranging from 5 to 200 µM). For the gemcitabine and KP-1212 drug 
combination, we observed an unexpected trend:  low concentrations of KP-1212 
(5 to 50 µM) enhanced the antiviral activity of gemcitabine, whereas high 
concentrations partially (100 µM) or fully (200 µM) antagonized the antiviral 
activity (Figure VI-3A). Similarly, the corresponding mutant frequencies 
increased to a maximum of 4.8-fold at 25 µM KP-1212 and then decreased to 
levels lower than for gemcitabine alone (Figure VI-3B). KP-1212 likely 
antagonized gemcitabine at high concentrations because they are both 
deoxycytidine analogs that require transport and metabolic conversion to their 
active forms. Specifically, they may utilize the same transporter proteins to 
breach the plasma membrane (either through facilitated diffusion or active 
transport), and they are both phosphorylated by deoxycytidine kinase to become 
active within cells (Heinemann et al., 1988; Huang et al., 1991; Mackey et al., 
1998; Murakami et al., 2005). Furthermore, the drugs were simultaneously added 
to cells, and KP-1212 was used at a much higher concentration than gemcitabine 
(10,000-fold higher for 200 µM KP-1212). Our observation of potential drug 
127 
 
interference could likely be circumvented by 1) using a more potent mutagenic 
deoxycytidine analog, 2) using a mutagenic nucleoside analog that is not 
phosphorylated by deoxycytidine kinase, 3) applying the drugs sequentially 
rather than simultaneously, or 4) using an RNRI that is not a nucleoside analog. 
Figure VI-3 KP-1212 potentiates the antiviral and mutagenic activities of RNRIs against HIV-1. 
Cells were pre-treated with a set amount of each ribonucleotide reductase inhibitor (RNRI) and 
varying amounts of KP-1212 (from 0 to 200 µM) as described in Section 3.4. Flow cytometry was 
used to determine HIV-1 infectivity (A) and mutant frequency (B), which were plotted relative to no 
drug. Statistical significance of drug combinations relative to both single drugs was assessed 
using a two-way ANOVA. * p-value < 0.05, ** p-value < 0.01, *** p-value <0.001. The data  
shown represent the mean ± sd of three independent experiments. 
We therefore examined the interactions of KP-1212 with two non- 
nucleoside RNRIs—resveratrol and deferoxamine. The addition of KP-1212 (5 to 
128 
 
200 µM) to resveratrol (50 µM) resulted in a concentration-dependent decline in 
viral infectivity, with the greatest potentiation observed at 200 µM KP-1212 
(Figure VI-3A). We observed a similar, though less concentration-dependent, 
trend for the combination of KP-1212 with deferoxamine. For both of these 
combinations, we also observed increases in the viral mutant frequencies (to a 
maximum of 6.2-fold for resveratrol and 4.7-fold for deferoxamine relative to that 
of no drug) (Figure VI-3B). These results indicate, in contrast to gemcitabine, 
high concentrations of KP-1212 were superior compared of that of low 
concentrations for potentiating the antiviral activity of resveratrol and 
deferoxamine. The elevation of the viral mutant frequency by the drug 
combinations is consistent with an increase in virus mutational load as a major 
mechanism of antiretroviral activity. 
KP-1212 potentiates the anti-HIV-1 activity of RNRIs without enhancing 
cytotoxicity 
To further characterize these drug combinations, we investigated the 
extent to which KP-1212 can augment the potency of RNRIs. We found that the 
addition of KP-1212 at a fixed amount (5 µM for gemcitabine or 200 µM for 
resveratrol) enhanced the potency of both gemcitabine and resveratrol, as 
evidenced by the significant decrease in EC50 values upon addition of KP-1212 
(Table VI-1). The greatest enhancement was observed for resveratrol, with the 
EC50 approximately halved.  The effect was much less for gemcitabine, as only 
low concentrations of KP-1212 could be used due to antagonism. The effect of 
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KP-1212 in combination with deferoxamine was not statistically significant 
compared to deferoxamine alone. We then examined the effect of the drugs 
(alone and in combination) on cell viability in order to determine whether drug 
cytotoxicity could explain the antiviral effects observed.  For gemcitabine, some 
degree of cytotoxicity was observed at all concentrations tested, but the CC50 
was higher than the EC50 (62.0 µM vs. 27.5 nM), indicating that the antiviral 
activity of gemcitabine cannot be explained by cytotoxicity (Figure VI-4 & Table 
VI-1). We also performed combustion analysis to confirm high purity of drug 
stocks, and conducted a separate cytotoxicity assay (trypan blue staining) to 
confirm cytotoxicity results (data not shown).  Taken together, we conclude that 
gemcitabine has low cytotoxicity in this cell line, possibly due to inactivation by 
rapid deamination of gemcitabine to its major metabolite, 2',2'-difluoro-2'- 
deoxyuridine (dFdU) (Abbruzzese et al., 1991; Heinemann et al., 1992). Unlike 
gemcitabine, KP-1212 was non-toxic up to 200 µM (data not shown), and the 
addition of KP-1212 (5 µM) did not alter the cytotoxicity of gemcitabine (Figure 
VI-4 & Table VI-1). These results indicate that enhanced cytotoxicity cannot 
explain the potentiation of the antiviral activity of gemcitabine by KP-1212. 
Similarly, the antiviral activity of resveratrol also could not be explained by 
cytotoxicity, as the CC50 was markedly higher than the EC50 (>400 µM; Figure 
VI-4 & Table VI-1). Furthermore, the addition of KP-1212 (200 µM) did not 
significantly alter the cytotoxicity of resveratrol.  In summary, KP-1212 
potentiates the antiviral activity of gemcitabine and resveratrol without 
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augmenting cytotoxicity, which improves their selectivity indices against HIV-1 
(Table VI-1). 
Table VI-1 KP-1212 improves the antiretroviral potency of RNRIs without altering 
cytotoxicity. 
- KP-1212 + KP-1212 
Drug EC50 CC50 SI EC50 CC50 SI 
Gemcitabine 27.5 nM 
(26.0-29.1) 
2250 21.6 nM 
(20.9- 
22.3) 
2970 62.0 µM 
(59.0-65.2) 
64.2 µM 
(60.8-67.8) 
Resveratrol 99.6 µM 
(92.5- 
> 400 µM > 4.0 52.8 µM 
(39.1- 
> 400 µM > 7.6 
107.4) 71.2) 
a The EC   and CC values for ribonucleotide reductase inhibitors (RNRIs) in the presence or 50 50 
absence of KP-1212 (5 µM for gemcitabine; 200 µM for resveratrol/deferoxamine) in U373-MAGI 
cells were calculated as described in the Materials and Methods. 
b Selectivity indices were determined by dividing the CC by the respective EC  . The 95% 50 50 
confidence intervals are indicated in parentheses. The data shown represent the mean ± sd of at 
least three independent experiments. 
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Figure VI-4 The ability of KP-1212 to potentiate RNRIs is not due to enhanced cytotoxicity. 
U373-MAGI cells were treated with ribonucleotide reductase inhibitors (RNRIs) ± KP-1212 (5 µM 
for gemcitabine, 200 µM for resveratrol and deferoxamine) for 24 h, then washed and replenished 
with fresh media. Cell viability was assessed 24 h after molecule removal using a luminescent 
ATP-based kit, and the data were normalized to the no drug control. The data shown are the 
mean ± sd of four independent experiments. 
Characterization of viral mutation spectra in the presence of KP-1212 and 
RNRIs 
To determine the types of mutations resulting from these drugs (i.e., 
individually and in combination), we sorted out mCherry+/GFP- cells infected in 
the presence or absence of drug. We then amplified and performed Sanger 
sequencing of the gfp gene. We chose not to include deferoxamine in this 
analysis due to its poor potency against HIV-1 (Table VI-1). We obtained a total 
of 376 unique mutations across all treatments, but several G-to-A hypermutants 
(likely a result of APOBEC3 activity) were excluded from further analysis (see 
"characterization of mutation spectra" in the materials and methods section for 
details), lowering the total number of mutations to 303.  In the absence of drug, 
G-to-A mutations were the most common, followed by A-to-G, T-to-C, and C-to-T 
transitions, with the remainder representing transversions (Figure VI-5).  In the 
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presence of only gemcitabine or resveratrol, no statistically significant (p < 0.05; 
2-way Fisher’s exact test) change in the relative appearance of each mutation 
type within the HIV-1 mutation spectrum was observed compared to the no drug 
control, suggesting that these drugs did not cause an increase in any particular 
mutation type. KP-1212, despite having only a modest ability to elevate the 
mutant frequency of HIV-1, caused a significant increase (p-value = 0.004) in the 
frequency of G-to-C mutations (from 1% to 22% of all mutations identified, 
relative to that of no drug), a transversion mutation rarely observed during HIV-1 
replication. Strikingly, the combination of KP-1212 with resveratrol led to an even 
greater increase in the frequency of G-to-C mutations (up to 41% of all 
substitutions identified), which is significantly different from either resveratrol 
alone (p-value < 0.0001) or KP-1212 alone (p-value = 0.048). The combination 
of KP-1212 and gemcitabine did not result in a significant increase in the 
frequency of G-to-C mutations (p-value = 0.130), likely due to a lower 
concentration of KP-1212 used in this combination (i.e., 5 µM versus 200 µM) 
due to drug antagonism observed at higher concentrations of KP-1212. 
133 
 
Figure VI-5 Characterization of viral mutation spectra in the presence of KP-1212 and RNRIs. 
U373-MAGI cells were pre-treated with KP-1212 and/or ribonucleotide reductase inhibitors 
(RNRIs) and infected with HIV-1. mCherry+/GFP- cells were sorted to enrich for mutants, and 
the gfp gene was amplified and sequenced. Each number in a wedge of a pie chart represents 
the specific corresponding mutational type, expressed as the percentage of the total mutations 
observed for that treatment. The total number of mutations sequenced were: no drug, 45, 
gemcitabine (Gem), 38; resveratrol (Res), 45; KP-1212, 49; gemcitabine + KP-1212, 57; 
resveratrol + KP-1212, 69 (303 mutations in total). Statistically significant (p-value < 0.05) 
changes relative to the no drug control are indicated with an asterisk. 
KP-1212 has not been previously found to induce G-to-C transversions, 
but 5-aza-2’-deoxycytidine (decitabine) and its ribonucleoside counterpart (5- 
AZC), have been reported to cause G-to-C transversions in HIV-1 and cellular 
genomic DNA (Clouser et al., 2010; Dapp et al., 2009; Jackson-Grusby et al., 
1997). These molecules decompose in water at physiological temperature and 
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pH by hydrolytic opening and deformylation of the triazine ring (Beisler, 1978; 
Chan et al., 1979; Lin et al., 1981; Liu et al., 2006; Rogstad et al., 2009; Yoo et 
al., 2007). The resulting ring-opened guanylurea derivatives are thought to pair 
with cytosine leading to G-to-C transversions (Jackson-Grusby et al., 1997). It is 
unclear how KP-1212 might induce G-to-C transversions, as KP-1212 should be 
resistant to hydrolysis. 
Conclusions 
While KP-1212 exerted minimal antiviral and mutagenic activity against 
HIV-1 in our assay, it was able to enhance the antiviral activities of the RNRIs 
gemcitabine and resveratrol, leading to robust reductions in HIV-1 infectivity and 
improvement of their selectivity indices. We found that the combinations 
simultaneously elevated the mutant frequency of HIV-1, suggesting 
enhancement of virus mutational loads as a major mechanism of the drug 
combinations. While the RNRIs gemcitabine and resveratrol do not appear to 
cause a specific type of mutation, the addition of KP-1212 to resveratrol led to a 
pronounced increase in G-to-C transversion mutations.  Further studies of the 
antiretroviral mechanisms of these combinations are warranted, as are efforts to 
identify prodrug forms and derivatives exhibiting reduced toxicity, improved 
potency, and prolonged stability.  Our findings suggest that the enhancement of 
viral mutant frequency is a major contributor to these antiviral mechanisms, but 
do not preclude other activities – such as inhibition of reverse transcription. 
Resveratrol, while well-tolerated, has low bioavailability due to rapid and 
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extensive metabolism in a number of clinical trials (Patel et al., 2011) but may 
serve as a lead for further development. It would also be of great interest to 
investigate the interplay of RNRIs and KP-1212 with conventional anti-HIV-1 
inhibitors. Previous studies have shown that these inhibitors can accelerate 
mutagen-driven viral extinction. This has been demonstrated for HIV-1 using 
AZT and 5-hydroxy-2’-deoxycytidine in combination and in foot-and-mouth 
disease virus, in which case sequential treatments were superior to combination 
therapy (Perales et al., 2009; Tapia et al., 2005). Overall, our findings are the first 
to demonstrate that a mild anti-HIV-1 mutagen can significantly potentiate the 
antiretroviral activity of RNRIs.  These observations may enhance the potential 
for clinical translation of KP-1212 for the treatment of HIV-1 infection. 
Materials and methods 
Plasmids, cell lines, and reagents 
The molecular clone of HIV-1 we used to produce virus, pNL4-3 MIG, was 
created from pNL4-3 HIG, which has been previously described (Clouser et al., 
2010). The virus encoded by this plasmid contains mCherry, an internal ribosome 
entry site (IRES), and enhanced green fluorescent protein (GFP). We 
pseudotyped virions with VSV-G expressed from pHCMV-G, a kind gift from J. 
Burns (University of California, San Diego). The human embryonic kidney (HEK 
293T) cells were purchased from American Type Culture Collection (Manassas, 
VA) and maintained in Dulbecco's Modified Eagle's Medium (DMEM) from 
Cellgro (Manassas, VA) with 10% HyClone FetalClone III (FC3) from Thermo 
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Scientific (Waltham, MA) and 1% penicillin/streptomycin from Invitrogen 
(Carlsbad, CA). U373-MAGI-CXCR4CEM cells were obtained from Michael 
Emerman through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH 
(Vodicka et al., 1997). U373-MAGI cells were maintained similarly to 293T cells 
but with addition of 1.0 µg/mL puromycin, 0.1 mg/mL hygromycin B, and 0.2 
mg/mL neomycin to the medium. The chemicals investigated were obtained from 
Sigma-Aldrich (deferoxamine and resveratrol; St. Louis, MO), Carbosynth (5-AZC 
and gemcitabine; Compton, UK), and Berry & Associates (KP-1212; Dexter, MI), 
dissolved in the appropriate solvent, and stored at -20 ºC.  For cloning, PCR was 
performed using the Platinum PCR Supermix from Invitrogen, while restriction 
enzymes, Klenow fragment, and T4 DNA ligase were from New England Biolabs 
(Ipswich, MA). For transfections, poly-L-lysine was from Newcomer Supply 
(Middleton, WI), and polyethylenimine (PEI) was from Polysciences, Inc. 
(Warrington, PA). 
Construction of an mCherry/GFP HIV-1 vector for rapid mutation detection 
The mCherry gene was swapped with the mouse heat stable antigen (hsa) 
in pNL4-3 HIG to generate pNL4-3 MIG as follows. From NL4-3 HIG, an IRES- 
GFP fragment was amplified via PCR and cloned into a pEGFP-N1-based 
mCherry vector using NotI and XbaI. The NotI site was then destroyed by fill-in 
with large Klenow fragment. The entire MIG cassette was then amplified using 
primers that added a NotI site to the 5’ end and a XhoI site to the 3’ end of the 
cassette. The PCR product was directly digested with NotI and XhoI and ligated 
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into NotI and XhoI-digested pNL4-3 HIG using T4 DNA ligase. The resulting 
plasmid, pNL4-3 MIG, expresses mCherry and GFP as well as all viral proteins 
except Env and Nef. 
Virus production and titering 
Virus was produced by co-transfecting pNL4-3 MIG and pHCMV-G into 
293T cells via the PEI method (Boussif et al., 1995). PEI stocks were prepared at 
1 mg/mL by dissolving PEI in water, adjusting the pH to 7.0, and filtering through 
a 0.2 µM filter. Stocks were divided into 1 mL aliquots and frozen at -80 ºC. On 
the day before transfection, 4 million 293T cells were plated on each 10 cm plate 
(pre-coated with poly-L-lysine) to be transfected. For each plate, 10 µg pNL4-3 
MIG + 1 µg pHCMV-G + 33 µL 1 mg/mL PEI were mixed in a 1.6 mL 
microcentrifuge tube to a final volume of 1 mL using serum-free DMEM.  After 20 
minutes of incubation, the medium on the 293T cells was replaced and the DNA- 
PEI mixture was added. The medium was replaced the morning after 
transfection, and virus was collected ~48 hours post-transfection by filtering the 
supernatant through a 0.2 µm filter. Viral stocks were divided into 1 mL aliquots 
and frozen at -80 ºC. 
Prior to any drug treatments, viral stocks were first titered in U373-MAGI 
cells. The day before infection, 62,500 cells/well were plated in 12-well plates. 
The next day the media was replaced and varying amounts of virus ranging from 
1.25 to 40 µL were added. The media was replaced again 24 hours post- 
infection and cells were collected at 72 hours post-infection for analysis by flow 
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cytometry. The infectious titer was calculated from the flow data by adding all 
positive quadrants (mCherry+ only, GFP+ only, and mCherry+/GFP+) to 
determine infectivity and then plotting the volume of virus against infectivity. 
Drug treatments and infections 
Drug treatments were performed using U373-MAGI cells in 12-well plates 
similar to the way in which viral stocks were titered (Section 3.3). Two hours 
prior to infection, drugs (1-2 µL) were added to a final volume of 0.5 mL media in 
each well. Uninfected cells and no drug (DMSO only-treated cells) were included 
as controls.  After two hours, virus and additional media were added, resulting in 
a final volume of 1 mL in each well.  Drug concentrations were based on the final 
volume of 1 mL. The amount of virus added was targeted to achieve 15-30% 
infection (for the no drug control) based on the previously determined viral titer. 
Drugs were removed by replacing the media 24 hours post-infection. The cells 
were collected 72 hours post-infection for flow cytometry by treating with trypsin, 
pelleting at 500xg for 5 minutes, resuspending in 200 µL Dulbecco’s Phosphate- 
Buffered Saline (DPBS) + 2% FC3, and transferring to 96-well plates. 
Infectivity and mutant frequency determination by flow cytometry 
Cells were analyzed for mCherry and GFP expression on a BD LSR II flow 
cytometer (BD Biosciences; San Jose, CA). Cells were first gated based on 
forward scatter and side scatter, and a minimum of 10,000 gated cells were 
analyzed per sample. GFP was excited with a blue 488 nm laser and emission 
detected using 505LP and 525/50 filters. mCherry was excited by a custom 
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green 561 nm laser and emission detected using 595LP and 610/20 filters. It 
should be noted that early on in our work we determined that very little 
fluorescent compensation was necessary with this particular combination of 
fluorophores, lasers, and filters (data not shown).  These control experiments 
were performed by transfecting mCherry or GFP into 293T cells and then 
analyzing the transfected cells (either kept separately or mixed together) by flow 
cytometry. Flow cytometry data were examined in FlowJo v. 7.6.1 (Ashland, 
OR). Infectivity was determined by adding all three positive populations: 
mCherry+ only, GFP+ only, and mCherry+/GFP+.  Mutant frequency was 
calculated by dividing the single positive populations (mCherry+ only and GFP+ 
only) by all infected cells.  Double negative (mCherry-/GFP-) cells were excluded 
due to the difficulty in detecting these rare events; mutant frequency calculations 
are therefore underestimates. Infectivity and mutant frequency data were 
normalized to the no drug controls. 
Cellular toxicity analysis 
The cytotoxicity of drugs was assessed using the CellTiter-Glo 
Luminescent Cell Viability Assay from Promega (Madison, WI) following the 
manufacturer’s instructions. 5000 U373-MAGI cells/well were plated in 96-well 
plates the day before drug treatment. The following day the medium was 
replaced and drugs (alone or in combination) were added to a final volume of 200 
µL/well.  No drug (DMSO only) and no cell wells were included as controls. The 
luminescence was recorded using an Orion microplate luminometer from 
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Berthold Detection Systems (Huntsville, AL). The data were analyzed by first 
subtracting the no cell control value and then normalizing to the no drug control. 
Characterization of mutation spectra in HIV-1 
Infected mCherry+/GFP- U373-MAGI cells were sorted at the Masonic 
Cancer Center at the University of Minnesota using a BD FACSAria II. A 
minimum of 3000 cells were collected per sample. Genomic DNA was isolated 
by the High Pure PCR Template kit from Roche (Indianapolis, IN). GFP was 
amplified in a single PCR reaction using the Platinum PCR Supermix from 
Invitrogen and the primers 5’-CAAGCGTATTCAACAAGG-3’ and 5’- 
GCAATACAGCAGCTAACAATG-3’. The PCR product was ligated into pGEM-T 
(Promega) and the gfp gene was sequenced at Functional Biosciences, Inc. 
(Madison, WI) using the T7 promoter primer. Sequences were aligned to the 
reference and mutations identified using Lasergene (DNASTAR, Inc., Madison, 
WI). Duplicate mutations, presumably arising from PCR amplification, were 
excluded from analyses.  Several G-to-A hypermutants (multiple G-to-A 
mutations within the same sequence) were observed, and these likely resulted 
from APOBEC3 activity, as they occurred in a GA or GG dinucleotide context and 
were present in both the no drug as well as drug treatment samples. These rare 
events were excluded from the analyses due to their potential for creating false 
differences in the rate of G-to-A mutations between samples. 
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Statistical analyses 
All graphs were created in Microsoft Excel v 12.3.5 (Redmond, WA) or 
GraphPad Prism v 5.0 (GraphPad Software, Inc.; La Jolla, CA).  EC50 values of 
drugs (drug concentration at which there is a 50% reduction in viral infectivity) 
were determined by plotting normalized infectivity against the log-transformed 
drug concentrations and fitting a non-linear regression curve to the data. 
Likewise, CC50 values of drugs (drug concentration at which there is 50% 
cytotoxicity) were determined by plotting normalized cell viability against the log- 
transformed drug concentrations and fitting a non-linear regression curve to the 
data. Two-way ANOVA was performed using the statistical package R to 
compare the impact of drug combinations against single drugs on infectivity and 
mutant frequency.  All analyses were performed on the log-transformed data 
without normalization. Differences in mutation spectra were assessed using 
Fisher’s exact test in GraphPad Prism. 
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